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Abstract
Background
¹⁸F-FDFG uptake by brain tissue as measured by positron emission tomography (PET) is a well-established method for
assessment of brain function in people with dementia. Certain findings on brain PET scans can potentially predict the decline
of mild cognitive Impairment (MCI) to Alzheimer’s disease dementia or other dementias.
Objectives
To determine the diagnostic accuracy of the ¹⁸F-FDG PET index test for detecting people with MCI at baseline who would
clinically convert to Alzheimer’s disease dementia or other forms of dementia at follow-up.
Search methods
We searched the Cochrane Register of Diagnostic Test Accuracy Studies, MEDLINE, EMBASE, Science Citation Index,
PsycINFO, BIOSIS previews, LILACS, MEDION, (Meta-analyses van Diagnostisch Onderzoek), DARE (Database of
Abstracts of Reviews of Effects), HTA (Health Technology Assessment Database), ARIF (Aggressive Research Intelligence
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Facility) and C-EBLM (International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence-based
Laboratory Medicine) databases to January 2013. We checked the reference lists of any relevant studies and systematic
reviews for additional studies.
Selection criteria
We included studies that evaluated the diagnostic accuracy of ¹⁸F-FDG PET to determine the conversion from MCI to
Alzheimer’s disease dementia or to other forms of dementia, i.e. any or all of vascular dementia, dementia with Lewy bodies,
and fronto-temporal dementia. These studies necessarily employ delayed verification of conversion to dementia and are
sometimes labelled as ‘delayed verification cross-sectional studies’.
Data collection and analysis
Two blinded review authors independently extracted data, resolving disagreement by discussion, with the option to involve a
third review author as arbiter if necessary. We extracted and summarised graphically the data for two-by-two tables. We
conducted exploratory analyses by plotting estimates of sensitivity and specificity from each study on forest plots and in
receiver operating characteristic (ROC) space. When studies had mixed thresholds, we derived estimates of sensitivity and
likelihood ratios at fixed values (lower quartile, median and upper quartile) of specificity from the hierarchical summary ROC
(HSROC) models.
Main results
We included 14 studies (421 participants) in the analysis. The sensitivities for conversion from MCI to Alzheimer's
disease dementia were between 25% and 100% while the specificities were between 15% and 100%. From the
summary ROC curve we fitted we estimated that the sensitivity was 76% (95% confidence interval (CI): 53.8 to 89.7)
at the included study median specificity of 82%. This equates to a positive likelihood ratio of 4.03 (95% CI: 2.97 to
5.47), and a negative likelihood ratio of 0.34 (95% CI: 0.15 to 0.75). Three studies recruited participants from the
same Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort but only the largest ADNI study (Herholz 2011) is
included in the meta-analysis. In order to demonstrate whether the choice of ADNI study or discriminating brain
region (Chételat 2003) or reader assessment (Pardo 2010) make a difference to the pooled estimate, we performed five
additional analyses. At the median specificity of 82%, the estimated sensitivity was between 74% and 76%. There was no
impact on our findings. In addition to evaluating Alzheimer's disease dementia, five studies evaluated the accuracy of ¹⁸F-
FDG PET for all types of dementia. The sensitivities were between 46% and 95% while the specificities were between 29%
and 100%; however, we did not conduct a meta-analysis because of too few studies, and those studies which we had found
recruited small numbers of participants. Our findings are based on studies with poor reporting, and the majority of included
studies had an unclear risk of bias, mainly for the reference standard and participant selection domains. According to the
assessment of Index test domain, more than 50% of studies were of poor methodological quality.
Authors' conclusions
It is difficult to determine to what extent the findings from the meta-analysis can be applied to clinical practice. Given the
considerable variability of specificity values and lack of defined thresholds for determination of test positivity in the included
studies, the current evidence does not support the routine use of ¹⁸F-FDG PET scans in clinical practice in people with MCI.
The ¹⁸F-FDG PET scan is a high-cost investigation, and it is therefore important to clearly demonstrate its accuracy and to
standardise the process of ¹⁸F-FDG PET diagnostic modality prior to its being widely used. Future studies with more uniform
approaches to thresholds, analysis and study conduct may provide a more homogeneous estimate than the one available
from the included studies we have identified.
Plain language summary
¹⁸F-FDG PET scan for early prediction of developing Alzheimer’s disease or other dementia in people with mild
cognitive impairment (MCI)
Background
The numbers of people with dementia and other cognitive problems are increasing globally. A diagnosis of dementia at early
stage is recommended but there is no agreement on the best approach. A range of tests have been developed which
healthcare professionals can use to assess people with poor memory or cognitive impairment. In this review we have
focused on the ¹⁸F-FDG PET test.
Aim
We aimed to see how accurately the ¹⁸F-FDG PET scan identified those people with MCI who would clinically convert to
Alzheimer’s disease dementia or other types of dementia over a period of time.
Study characteristics
The evidence is current to January 2013. We included 16 studies covering 697 participants with MCI. The studies have been
published over a 14-year period (1999 to 2013). Study sizes were small and ranged from 19 to 94 participants. Five papers
have a mean age of less than 70 years. The age range in the youngest sample was 55 to 73 years and in the oldest sample
was 71 to 86 years. Participants were mainly recruited from university departments, clinics or research centres. The
percentage of participants with positive ¹⁸F-FDG PET scans at baseline ranged in the included studies from 10.5% to 74%
and the percentage of those participants who converted to Alzheimer’s disease dementia over a period of time ranged from
22% to 50%. Included studies reported a range of different cut-off values used for identifying their participants with positive
¹⁸F-FDG PET scans.
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Quality of the evidence
Our findings are based on studies with poor reporting. The majority of included studies had an unclear risk of bias, mainly
because they did not describe in sufficient details how participants were selected and how the clinical diagnosis of
Alzheimer’s disease dementia was justified. According to the assessment of the ¹⁸F-FDG PET test domain, more than 50% of
studies were of poor methodological quality.
The main limitations of the review are poor reporting in the included studies, a lack of a widely-accepted cut-off value of the
¹⁸F-FDG PET scan in people with MCI, and the marked variation in test accuracy between the included studies.
Key findings
In this review, we have found that the ¹⁸F-FDG PET scan, as a single test, lacks the accuracy to identify those people with
MCI who would develop Alzheimer’s disease dementia or other forms of dementia over a period of time. Assuming a typical
conversion rate of MCI to Alzheimer’s disease dementia of 38%, the findings indicate that for every 1000 ¹⁸F-FDG PET
scans, 174 cases with a negative scan will progress to Alzheimer's disease dementia and 285 with a positive scan will not.
Therefore, a positive ¹⁸F-FDG PET scan in people with MCI is of no clinical value in early prediction of developing
Alzheimer's disease dementia.
Background 
The most common form of dementia in the general population is Alzheimer’s disease. It is useful to distinguish the term
Alzheimer's disease, which refers to underlying pathology, from Alzheimer's disease dementia, which is the final stage of a
clinical syndrome associated with the pathology.
Alzheimer’s disease dementia (ADD) afflicts 5% of men and 6% of women over the age of 60 worldwide (ICD-10 2010).
The prevalence increases exponentially with age as Alzheimer’s disease dementia affects fewer than 1% of people
aged 60 to 64, but 24% to 33% of those over 85 (Ferri 2005). The earliest symptoms of ADD include short-term
memory loss, a gradual decline in other cognitive abilities and behavioural changes. Cortical intracellular neurofibrillary
tangles (NFT) and extracellular β-amyloid (Aβ) plaques (Braak 1991) represent the neuropathological features of
Alzheimer's disease dementia and are responsible for synapse dysfunction, neuronal cell loss and consequent brain
atrophy (Ballard 2011). According to the National Institute of Neurological and Communicative Disorders and
Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (McKhann 1984), definite
Alzheimer's diseases dementia can only be diagnosed following neuropathological examination of brain tissue, obtained by
biopsy or autopsy.
Mild cognitive impairment (MCI) represents a possible intermediary condition between normal cognition and dementia (
Morris 2001; Petersen 2009). Currently, 16 different classifications are used to define MCI (Matthews 2008). The
different definitions of MCI are based on general criteria that include a cognitive complaint (self- or informant-
reported or both), preserved basic activities of daily living, cognitive impairment (not normal for age and education)
or decline in cognition evidenced by performance on objective cognitive tasks, and absence of dementia (Petersen 2004; 
Winblad 2004). In this review MCI refers to the clinical criteria defined by Petersen and Winbald (Petersen 1999; Petersen
2001; Petersen 2004; Winblad 2004), or the Clinical Dementia Rating (CDR) scale (CDR = 0.5) (Morris 1993), or any of the
16 descriptions of MCI reported by Matthews 2008.
There are four outcomes for those within an MCI population: progression to ADD, progression to another dementia,
maintaining stable MCI, or recovery. An early identification of those people who would convert from MCI to ADD and
other forms of dementia may improve the opportunities for early intervention and might help their carers to plan the
future. However, current data in the medical literature are still not adequate to guide clinicians and researchers in
understanding the progression of dementia. There is no clinical method to predict the possible conversion of people
with MCI to ADD or other dementias. Studies (Bruscoli 2004; Mattsson 2009; Petersen 1999; Petersen 2009) indicate
that an annual average of 10% to 15% of people with MCI progress to ADD. This all depends on clinical profile,
settings and investigation for vascular disease. Thus, the improvement of diagnostic accuracy is critical for the
management and treatment of ADD and other dementias. Research suggests that measurable change in positron
emission tomography (PET), magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers occurs
years in advance of the onset of clinical symptoms (Beckett 2010). This review focuses on the relation between the ¹⁸F-2-
fluoro-2-deoxy-D-glucose (¹⁸F-FDG)-PET biomarker results, the brain tissue glucose metabolism at baseline, and i)
‘conversion from MCI to Alzheimer’s disease dementia’ or ii) ‘conversion from MCI to other forms of dementia’ at follow-up.
Target condition being diagnosed
The primary target condition is Alzheimer's disease dementia. The diagnosis is based on the exclusion of other
causes of dementia through clinical, paraclinical and neuropsychological investigations criteria as indicated in the
NINCDS-ADRDA guidelines (McKhann 1984). Exclusion of other diseases such as depression, hypothyroidism,
and non-Alzheimer's disease brain lesions is a fundamental part of the diagnostic process (McKhann 1984). A standard
diagnostic practice is based on clinical examinations and neurological and mental status examination of the patient.
Moreover, the standard diagnostic practice includes caregiver or family member interviews, focusing on progressive cognitive
impairments and behavioural changes associated with the disease.
The secondary target condition is any other form of dementia, including all-cause dementia (APA 1987; APA 1994),
vascular dementia (Román 1993), dementia with Lewy bodies (McKeith 2006), and fronto-temporal dementia (Lund
Manchester 1994; Neary 1998).
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Index test(s)
PET represents a unique, minimally invasive diagnostic nuclear medicine modality of well-documented accuracy. It assesses
pathophysiologic and chemical processes by using radiopharmaceuticals that mimic endogenous molecules. Depending on
the distribution of the radiotracer in the human body, images are produced and diagnostic information is acquired. Kinetic
information may also be available. ¹⁸F-FDG is the most common molecular imaging biomarker used in PET. In particular, ¹⁸F-
FDG is a radiolabeled glucose analogue and thus by entering the glucose metabolic pathway provides information about
tissue metabolism. In other words, ¹⁸F-FDG is an indicator of intracellular glucose metabolism. It has a wide variety of
applications in neurosciences, oncology, and cardiology.
¹⁸F-FDG uptake by brain tissue as measured by PET is a well-established method for evaluation of brain function
and it has been used in the study of dementia for more than three decades. ¹⁸F-FDG PET evaluates the regional
cerebral metabolic rate for glucose (rCGMr), thus giving information about the entity of neuronal loss or synapse
dysfunction The key finding is the reduced brain glucose metabolism that is associated with neurodegenerative
diseases. Glucose metabolism imaging with ¹⁸F-FDG is the most sensitive and specific imaging modality available
today for the diagnosis of ADD (Lucignani 2006). Furthermore, ¹⁸F-FDG PET is nowadays considered an imaging
biomarker for Alzheimer's disease before onset of dementia and in clinical trials (Bohnen 2012; Dubois 2010; Hampel 2010
). Hypometabolism in the temporo-parietal lobe, as assessed by qualitative visual interpretation of the PET scan,
represents the typical pattern found in ADD (Herholz 2002; Nitrini 2000). Moreover, it has been demonstrated that
progression of neurodegenerative changes in people with ADD and other dementias is associated with both more
cognitive impairment and larger PET metabolic deficits (Duara 1986; Haxby 1986).
The ¹⁸F-FDG PET pattern for MCI is not so consistent, which is unsurprising, due to the variable physical history of
the disorder. However, people with MCI usually present on PET with mild global and regional hypometabolism (Mosconi
2009). ¹⁸F-FDG PET studies have found characteristic and progressive cerebral metabolic rate for glucose (CMRgl)
reductions in posterior cingulate, precuneus, parietal, temporal and frontal regions in both ADD and in people with MCI,
with the findings being more pronounced in those with MCI who eventually converted to ADD (Chen 2010; Morbelli 2010; 
Patterson 2010). Moreover, a growing body of ¹⁸F-FDG PET studies have been carried out specifically in order to
evaluate the correlation between glucose metabolism impairment and the progression from MCI to ADD and other
dementias. These studies suggest that certain findings on brain PET scans can potentially predict the decline of
MCI to ADD. In agreement with this, a recent meta-analysis points out that people converting from MCI, in
comparison with those who did not convert to ADD, showed hypometabolism/hypoperfusion in the parietal lobe (Schroeter
2009). Further, Laforce 2010 studied the role of ¹⁸F-FDG PET in the diagnosis of atypical/unclear dementias in a cohort of 94
people suffering from MCI or dementia. Their results showed that PET significantly reduced the percentage of unclear
dementia diagnoses from 39% to 16%.
The mainstay in ¹⁸F-FDG PET interpretation is the visual reading of the scan, which depends heavily on the
experience and previous training of the reading physician. This reliance on the observer’s qualitative interpretation
and the lack of well-defined thresholds for differentiation of pathological from normal scans is an issue regarding
the application of the modality in the diagnostic work-up of people with MCI. Nevertheless, the development and
utilisation in recent years of new software tools for image analysis have helped in the direction of carrying out many
brain ¹⁸F-FDG PET studies. These software applications, some of which are currently Food and Drug
Administration (FDA)-approved, have enabled the quantification of brain PET scans, achieving objective evaluation
and thus increasing the physician's interpretative confidence. Although subjective (visual) interpretation of the brain
scan is the general standard in clinical practice, the addition of quantitative information can be crucial in such
studies, since it improves the diagnostic accuracy (Patterson 2010).
Clinical Pathway 
Dementia develops over a trajectory of several years. There is a presumed period when people are asymptomatic, and when
pathology is accumulating. Individuals or their relatives may then notice subtle impairments of recent memory. Gradually,
more cognitive domains become involved, and difficulty in planning complex tasks becomes increasingly apparent. In the UK,
people usually present to their general practitioner, who may administer some neuropsychological tests, and will potentially
refer them to a hospital memory clinic. However, many people with dementia do not present until much later in the disorder
and will follow a different pathway to diagnosis, for example being identified during an admission to a general hospital for a
physical illness. Thus the pathway influences the accuracy of the diagnostic test. The accuracy of the test will vary with the
experience of the administrator, and the accuracy of the subsequent diagnosis will vary with the history of referrals to the
particular healthcare setting. Diagnostic assessment pathways may vary between countries and diagnoses may be made by
a variety of specialists including neurologists and geriatricians. 
Alternative test(s)
We are not including alternative tests in this review because there are currently no standard practice tests available for the
diagnosis of dementia. 
The Cochrane Dementia and Cognitive Improvement Group (CDCIG) is in the process of conducting a series of diagnostic
test accuracy reviews of biomarkers and scales (see list below). Although we are conducting reviews on individual tests
compared to a reference standard, we plan to compare our results in an overview.
¹¹C-PIB PET( Pittsburgh Compound-B positron emission tomography)
CSF (Cerebrospinal fluid analysis of abeta and tau)
sMRI (structural magnetic resonance imaging)
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Neuropsychological tests (MMSE; Mini-Cog; MoCA)
Informant interviews (IQCODE; AD8)
APOE ε4 (apolipoprotein ε4 allele gene)
rCBF SPECT (regional cerebral blood flow single photon emission computerised tomography)
Rationale
According to the latest revised NINCDS-ADRA diagnostic criteria for ADD of the National Institute on Aging and
Alzheimer Association (Albert 2011; Dubois 2010; McKhann 2011; Sperling 2011), the confidence in diagnosing MCI due to
Alzheimer's disease is raised with the application of biomarkers based on imaging or CSF measures. These tests, added to
core clinical criteria, might increase the sensitivity or specificity of a testing strategy. However, it is crucial that each of these
biomarkers is assessed for their diagnostic accuracy before they are adopted as routine add-on tests in clinical practice.
The ¹⁸F-FDG PET biomarker, as the extra diagnostic criterion, might facilitate accurate identification of those people
with MCI who would convert to ADD or other forms of dementia. At the present time there is no 'cure' for dementia, but
there are some treatments which can slow cognitive and functional decline, or reduce the associated behavioural and
psychiatric symptoms of dementia (Birks 2006; McShane 2006). In addition, the accurate early diagnosis of dementia
may improve opportunities for the use of newly-evolving interventions designed to delay or prevent progression to more
debilitating stages of dementia (Oddo 2004). Coupled with appropriate contingency planning, proper recognition of the
disease may also help to prevent inappropriate and potentially harmful admissions to hospital or institutional care (NAO
2007).
Objectives 
To determine the diagnostic accuracy of the ¹⁸F-FDG-PET index test for detecting people with MCI at baseline who would
clinically convert to ADD or other forms of dementia at follow-up. Although we want to identify whether 'early forms of
Alzheimer's disease dementia' are present at the moment of examination, there is no reference standard to make a final
diagnosis of early ADD. Follow-up is therefore needed to reconstruct what was going on at the time of the index examination.
In this context, it is clear that the duration of follow-up becomes critical, i.e. sufficiently long to capture the natural course of
conversion.
Secondary objectives
To investigate heterogeneity of test accuracy in the included studies.
We expect that heterogeneity will be likely and that it will be an important component of the review. The potential sources of
heterogeneity, which we will use as a framework for the investigation of heterogeneity, include target population, index test,
target disorder and study quality.
Methods 
Criteria for considering studies for this review
Types of studies 
We consider longitudinal cohort studies in which index test results are obtained at baseline and the reference
standard results at follow-up (see below for detail about the nature of the index test and reference standard). These
studies necessarily employ delayed verification of conversion to dementia and are sometimes labelled as ‘delayed
verification cross-sectional studies’ (Bossuyt 2004; Bossuyt 2008; Knottnerus 2002). 
We also consider case-control studies if they incorporate a delayed verification design. This occurs in the context of a
cohort study, so these studies are invariably diagnostic nested case-control studies. We only include data on performance of
the index test to discriminate between people with MCI who convert to dementia and those who remained stable from those
studies. We have not considered data from healthy controls or any other control group.
Participants
Participants recruited and clinically classified as those with MCI at baseline were eligible for this review. We include
studies that used the Petersen or revised Petersen criteria (Petersen 1999; Petersen 2004; Winblad 2004) or the
Clinical Dementia Rating (CDR = 0.5) scale (Morris 1993) or any of the 16 different classifications of MCI described by
Matthews 2008 as diagnostic criteria for MCI. Those criteria are presented in Table 1 and Table 2.
We exclude those studies that involve people with MCI possibly caused by: i) current use or history of alcohol/drug abuse; ii)
Central Nervous System trauma (e.g. subdural haematoma), tumour or infection; iii) other neurological conditions e.g.
Parkinson’s or Huntington’s diseases.
Index tests
¹⁸F-FDG PET biomarker test
There are currently no generally accepted standards for a ¹⁸F-FDG positivity threshold, and therefore we have used the
criteria which were applied in each included primary study to classify participants as either ¹⁸F-FDG-positive or ¹⁸F-FDG-
negative, according to the degree of glucose metabolism in selected brain regions. Some studies apply a qualitative
assessment of PET scans, while some apply both qualitative and quantitative assessments. Moreover, different thresholds
are used in quantitative studies. While this may generate heterogeneity it should be noted that the addition of quantitative
analysis (in the interpretation of the ¹⁸F-FDG PET brain scan) in clinical practice is done in order to support the visual
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(qualitative) reading of the scan by the physician.
A range of thresholds have been used in primary research, for instance: i) "the regional cerebral glucose metabolism
ratio (rCGM-r) is lower than 80% of whole brain mean of control subjects" (Chételat 2003); ii) "the rCGM-r of temporo-
parietal and posterior cingulate < 1.3 - 8" (Anchisi 2005).
We considered the use of any image analysis technique, ¹⁸F-FDG injection dose, the time between ¹⁸F-FDG injection and
PET acquisition, and ¹⁸F-FDG reduction regions (e.g. parietal, temporal, frontal lobes, posterior cingulated, precuneus). The
exact administered ¹⁸F-FDG activity does not affect the PET examination (as long as it ranges between the accepted limits
for acquiring proper images), as this can be compensated for by the duration of the scan; the number of counts detected by
the scanner is the key finding.
The accepted limits of administered activity are defined by guidelines published by the Nuclear Medicine Societies.
The two major ones are the Society of Nuclear Medicine (SNM, USA) (Waxman 2009) and the European Association
of Nuclear Medicine (EANM, Europe) (Varrone 2009). According to SNM, the recommended ¹⁸F-FDG activity in adults for
brain PET is 185 - 740 MBq (or 5 - 20 mCi). According to EANM, the recommended administered activity for adults is 300 –
600 MBq (typically 370 MBq) in 2D mode and 125 – 250 MBq (typically 150 MBq) in 3D mode. All studies included in this
review demonstrated homogeneity in the protocol followed, with no substantial differences, regarding administered dose or
scanning acquisition followed. Moreover, despite the between-studies differences regarding interpretation criteria, the
evaluation of the PET scans was based on the fundamental principle of detection of a pattern of brain hypometabolism
(decreased ¹⁸F-FDG uptake) in people with MCI that is topographically consistent with the respective hypometabolic pattern
expected to be seen in ADD. This means detection of regional metabolic reductions mainly in the temporo-parietal and
posterior cingulate cortices.
The differences in exact timing of image acquisition also do not influence the study, as long as the acquisition does
not start earlier than 30 minutes after ¹⁸F-FDG injection. It is recommended, however, that each department follow a
standard protocol with a fixed time for starting the acquisition (e.g. 30 or 60 minutes after injection) (Varrone 2009; Waxman
2009). The aim of the acquisition is the good contrast between grey and white matter.
We did not include any comparator test because there are currently no standard practice tests available for the diagnosis of
dementia. We compared the index test with a reference standard.
Target conditions
There are two target conditions in this review:
1. Alzheimer’s disease dementia (conversion from MCI to Alzheimer’s disease dementia);
2. Other forms of dementia (conversion from MCI to other forms of dementia, i.e. any or all of vascular dementia, dementia
with Lewy bodies, or fronto-temporal dementia).
Reference standards
For the purpose of this review, several definitions of ADD are acceptable. We Included studies that applied
probable or possible NINCDS-ADRDA criteria (McKhann 1984). We also considered those studies that used the Diagnostic
and Statistical Manual of Mental Disorders (DSM) (APA 1987; APA 1994) and International Classification of Diseases
(ICD) (ICD-10 2010) definitions for ADD.
Similarly, differing clinical definitions of other dementias are acceptable. For Lewy body dementia the reference
standard is the McKeith criteria (McKeith 1996; McKeith 2006). For fronto-temporal dementia the reference standards
are the Lund criteria (Lund Manchester 1994), Neary 1998, Boxer 2005, DSM-III (APA 1987), DSM-IV (APA 1994),
ICD-9 (ICD-9 2006), ICD-10 (ICD-10 2010). For vascular dementia the reference standards are the NINDS-ARIEN
criteria (Román 1993), DSM-III (APA 1987), DSM-IV (APA 1994), ICD-9 (ICD-9 2006) and ICD-10 (ICD-10 2010).
The time interval over which progression from MCI to ADD or other forms of dementia occurs is important. We chose one
year as the minimum period of delay in the verification of the diagnosis (i.e. the time between the assessment at which a
diagnosis of MCI is made and the assessment at which the diagnosis of dementia is made).
Search methods for identification of studies 
We used a variety of information sources, aiming to retrieve as many relevant studies as possible. The Trials Search Co-
ordinator of the CDCIG devised search strategies for electronic database searching.
Electronic searches 
The most recent search for this review was performed in January 2013. We requested a search of the Cochrane
Register of Diagnostic Test Accuracy Studies (managed by the Cochrane Renal Group). We also searched
MEDLINE (OvidSP) (1950 to January 2013), MEDLINE (1950 to present), EMBASE (OvidSP) (1974 to week 2
2013), PsycINFO (OvidSP) (1806 to January week 2 2013), all databases in the Web of Science collection: Web of
Science (1945 to present); BIOSIS Previews (1926 to present); Journal Citation Reports, and LILACS (Bireme).
See Appendix 1 for details of the sources searched, the search strategies used, and the number of hits retrieved. We
did not apply any language or date restrictions to the electronic searches; we did not use methodological filters, so as
to maximise sensitivity (Beynon 2013; Whiting 2011).
Searching other resources 
We checked the reference lists of all relevant studies for additional studies. We also conducted searches in the MEDION
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database (Meta-analyses van Diagnostisch Onderzoek) at www.mediondatabase.nl, Database of Abstracts of Reviews of
Effects (DARE) at www.crd.york.ac.uk/CRDWeb/, Health Technology Assessments Database (HTA Database) at
www.crd.york.ac.uk/CRDWeb/, and Aggressive Research Intelligence Facility (ARIF) database at www.arif.bham.ac.uk for
other related systematic diagnostic accuracy reviews. We searched for systematic reviews of diagnostic studies from the
International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence-based Laboratory Medicine
database (C-EBLM). We checked reference lists of any relevant systematic reviews for additional studies.
Data collection and analysis 
Selection of studies 
The CDCIG Trials Search Co-ordinator (TSC), who is a researcher with experience of DTA systematic reviews, performed
the first assessment of the search results in order to remove the obviously non-relevant studies. Two review authors
independently reviewed the remaining titles and abstracts for potentially eligible studies for full paper review. Two review
authors then independently assessed full manuscripts against the inclusion criteria. Where necessary, a third review author
resolved disagreements that the other two were not able to resolve through discussion.
Where a study did not present all relevant data (for creating a 2 x 2 table) in the published manuscript, we contacted the
authors directly to request further information. When the same dataset was presented in more than one paper, we planned to
include the primary paper, which is the paper with the largest number of participants or with the most informative data.
We detailed the number of studies selected at each point in a Study flow diagram (below).
Data extraction and management
We extracted the following data on study characteristics (if reported):
Bibliographic details of primary paper:
Author, title of study, year and journal
Basic clinical and demographic details:
Number of participants
MCI clinical criteria
Age
Gender
Referral centre(s)
Participant recruitment
Sampling procedures
Details of the index test:
Method of the ¹⁸F-FDG PET index test administration, including who administered the test
Thresholds used to define positive and negative tests
Other technical aspects as seem relevant to the review, e.g. brain areas
Details of the reference standard:
Definition of ADD and other dementias used in reference standard
Duration of follow-up from time of index test used to define ADD and other dementias in reference standard: 1 to < 2
years; 2 to < 4 years; and > 4 years; if participants have been followed for varied amounts of time we recorded a mean
follow-up period for each included study
Prevalence or proportion of population developing ADD and other dementias, with severity, if described
We created 2 x 2 tables (cross-relating index test results of the reference standards) as shown in Appendix 2. We also
extracted data necessary for the assessment of quality, as defined below. Two blinded review authors (NS, CS) extracted
data independently, resolving disagreements in data extraction by discussion, and involving a third review author (CH) as
arbiter when necessary.
Assessment of methodological quality
We assessed the methodological quality of each study using the QUADAS-2 tool (Whiting 2011), as recommended by The
Cochrane Collaboration. The tool is made up of four domains: i) Participant selection; ii) Index test; iii) Reference standard;
iv) Participant flow.
Two independent raters (NS, SM), blinded to each other’s scores, performed the QUADAS-2 assessment, resolving
disagreement by further review and discussion, with potential to involve a third review author (CH) as arbiter if necessary.
We assessed each domain in terms of risk of bias, with the first three domains also considered in terms of applicability. The
components of each of these domains and a rubric which details how judgements concerning risk of bias are made are
detailed in Appendix 3 and Appendix 4. Certain key areas important to quality assessment are participant selection, blinding
and missing data.
We did not use QUADAS-2 data to form a summary quality score in order to ensure that the nature of the limitations of the
studies were as transparent as possible. We produced a narrative summary describing numbers of studies that were found to
have high/low/unclear risk of bias as well as concerns regarding applicability.
Statistical analysis and data synthesis
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We evaluated test accuracy according to target condition. There are no accepted thresholds to define ¹⁸F-FDG PET
positivity for Alzheimer's disease dementia and other forms of dementia, and so the estimates of diagnostic
accuracy reported in primary studies were likely to be based on data-driven threshold selection (Leeflang 2008). We
conducted exploratory analyses by plotting estimates of sensitivity and specificity from each study in forest plots and in
receiver operating characteristic (ROC) space. We meta-analysed pairs of sensitivity and specificity using the
hierarchical summary ROC (HSROC) model (Rutter 2001) which allows for the possibility of variation in threshold between
studies. Where inadequate studies were available to estimate all parameters, we assumed a symmetrical shape to the
summary ROC curve. Estimates of summary sensitivities and specificities are not clinically interpretable when studies with
mixed thresholds are included in the HSROC model, and so we derived estimates of sensitivity and likelihood ratios at fixed
values (lower quartile, median and upper quartile) of specificity from the HSROC models. We performed the analyses using
the SAS software (version 9.2; SAS Institute 2011, Cary, NC).
Investigations of heterogeneity
In preliminary analyses, we visually examined forest plots of sensitivity and specificity, and SROC plots to explore
the effect of the sources of heterogeneity. We investigated the effect of i) interpretation of PET scan (a
combination of visual inspection and quantitative rCGMr evaluation interpretation or visual-only interpretation) and
ii) prespecification of threshold on the diagnostic accuracy of the ¹⁸F-FDG PET index test. However as there were
insufficient studies we did not perform meta-regression (by including each potential source of heterogeneity as a
covariate in the HSROC model) as planned (Differences between protocol and review).
Sensitivity analyses
Due to the limited number of studies evaluating ¹⁸F-FDG PET for all dementia, we performed sensitivity analyses
only for studies of ADD. This is a departure from the protocol (Vacante 2013) and is explained in the Differences between
protocol and review section.
Assessment of reporting bias
We did not investigate reporting bias because of current uncertainty about how it operates in test accuracy studies and the
interpretation of existing analytical tools such as funnel plots.
Results 
Results of the search
The total number of records identified by the searches for this review was 9676. After de-duplication, the Trials Search
Co-ordinator and two paid assessors with experience of screening citations for biomarker diagnostic test accuracy
studies screened the titles and abstracts. In total, they assessed 397 full papers and conference abstracts for eligibility
(Figure 1). We included 16 papers, and discarded 349 for the following reasons: i) not MCI participants at
baseline; ii) not a longitudinal study; iii) index test not a ¹⁸F-FDG PET. In addition, we excluded 32 papers due
to insufficient data for creating 2 x 2 tables (Characteristics of excluded studies). We found no extra studies through
reference checking. We obtained usable data for seven studies (Anchisi 2005; Clerici 2009; Galluzzi 2010; Landau 2010; 
Ossenkoppele 2012a; Ossenkoppele 2012b; Schmand 2012) through contacting the authors.
Included Studies
The Characteristics of included studies table lists the details of the 16 included studies covering 697 participants with
MCI at baseline, of whom 595 had analysable data. Three studies (Landau 2010; Herholz 2011; Schmand 2012)
recruited participants from the same cohort (ADNI participants). The studies have been published over a 14-year
period (1999 to 2013). Most of them (13/16) were conducted in Europe (five in Italy, four in The Netherlands, two in
Germany, one in Sweden and one in France), and three in the USA. Fourteen included studies used a version of the
Petersen criteria for MCI. Thirteen studies applied NINCDS-ADRDA criteria as a reference standard for ADD (Berent 1999
also used ICD-10 while Clerici 2009 and Nobili 2008 also used DSM-IV; Fellgiebel 2007, Herholz 2011 and Pardo 2010 did
not specify the reference standard at follow-up).
Demographic and participant characteristics are summarised in Table 3. Study sizes were small and ranged from 19 to
94 participants. Five papers have a mean age of under 70 years (Arnáiz 2001; Fellgiebel 2007; Mosconi 2004; 
Ossenkoppele 2012a; Ossenkoppele 2012b); Schmand 2012 did not report demographic data on the sample
with ¹⁸F-FDG PET scan. The youngest sample was aged 64.0 ± 9.0 (Ossenkoppele 2012b) and the oldest sample
was aged 78.3 ± 7.5 (Landau 2010). Seven studies included more men than women in the samples included in
the analysis (range from 33% to 75%); three studies did not reported gender for those samples (Ossenkoppele 2012b; 
Pardo 2010; Schmand 2012). APOE Ɛ4 gene carriers and sampling procedure were poorly reported. Participants
were mainly recruited from university departments, clinics or research centres (seven studies) while three studies did
not report their sources of recruitment (Chételat 2003; Mosconi 2004; Ossenkoppele 2012a). Most of the studies did not
clearly report whether participants were recruited from secondary or tertiary outpatient care settings.
Table 4 summarises the data regarding the threshold used, image scaling, brain region as potential Alzheimer's disease
areas, ¹⁸F-FDG dose and the time between ¹⁸F-FDG injection and performing a PET scan, the number of ¹⁸F-FDG-positive
participants at baseline and the number of converters during the follow-up period.
All included studies applied qualitative/visual evaluations of the PET scans. In particular, 12 of the 16 studies
performed PET analysis based on the combination of visual analysis (qualitative) and rCGMr estimations
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(quantitative), while the remaining four studies referred only to visual PET inspections (qualitative-only analysis). A
range of different thresholds were applied (different rCGMr values, various brain regions studied as potential
Alzheimer's disease areas, as well as different scaling). The threshold was prespecified in only six studies (Clerici 2009; 
Drzezga 2005; Fellgiebel 2007; Galluzzi 2010; Herholz 2011; Schmand 2012). ¹⁸F-FDG positivity ranged from 10.5%
(Mosconi 2004) to 74% (Galluzzi 2010) (Table 5). Conversion to ADD ranged from 22% (Mosconi 2004) to 50% (Berent
1999; Clerici 2009; Ossenkoppele 2012a).
Duration of follow-up was reported as the mean and standard deviation (SD), or the median, or a range of values.
Methodological quality of included studies
We assessed methodological quality using the QUADAS-2 tool (Whiting 2011). We present the review authors’ judgements
about each methodological quality item for each included study in the Characteristics of included studies table and Figure 2.
The overall methodological quality of included study cohorts is summarised in Figure 3.
In the participant selection domain, we considered five studies (Berent 1999; Chételat 2003; Herholz 2011; Landau 2010; 
Pardo 2010) to be at high risk of bias because the participants were not consecutively or randomly enrolled. We had
excluded studies with a case-control design because we only considered data on performance of the index test to
discriminate between participants with MCI who convert to dementia and those who remained stable. We considered
four studies (Arnáiz 2001; Galluzzi 2010; Nobili 2008; Schmand 2012) to be at unclear risk of bias due to poor reporting on
sampling procedure and exclusion criteria. We considered the remaining seven (44%) studies to be at low risk of bias.
In the index test domain, we considered nine (56%) studies (Anchisi 2005; Arnáiz 2001; Berent 1999; Chételat 2003; 
Landau 2010; Nobili 2008; Ossenkoppele 2012a; Ossenkoppele 2012b; Pardo 2010) to be at high risk of bias
because the threshold used was not prespecified and the optimal cut-off level was determined from ROC analyses;
therefore, the accuracy of the ¹⁸F-FDG biomarker reported in these studies appeared to be an overestimate. We
considered one study (Mosconi 2004) to be at unclear risk of bias due to poor reporting. We considered the remaining six
(38%) studies to be at low risk of bias.
In the reference standard domain, we considered 11 studies (69%) to be at unclear risk of bias, mainly because
they did not report whether clinicians conducting follow-up were aware of the initial ¹⁸F-FDG biomarker analysis
results. One of the 11 studies (Fellgiebel 2007) did not clearly report the reference standards used for diagnosing
ADD. We considered two studies (Herholz 2011; Pardo 2010) to be at high risk of bias because they failed to provide
information on either item in this domain. We were not able to obtain the information about how the reference standard
was obtained and by whom, due to poor reporting. We considered the remaining three studies (Berent 1999; Chételat 2003; 
Drzezga 2005) to be at low risk of bias.
In the flow and timing domain, we judged 10 studies (62%) to be at low risk of bias because all participants were
accounted for in the analysis or the reasons for missing data were given, and/or the time interval between index test
and reference standard was appropriate (duration of follow-up longer than one year). We considered three studies
(19%) to be at high risk of bias, either because a large number of participants were excluded from the analyses (Anchisi
2005; Ossenkoppele 2012b) or because the interval between index test and reference standard was shorter than one
year for some participants (Nobili 2008). We considered the remaining three studies (Clerici 2009 Fellgiebel 2007; Pardo
2010) to be at unclear risk of bias due to poor reporting.
For assessment of applicability, we had no concern that the included participants and setting, the conduct and
interpretation of the index test, and the target condition (as defined by the reference standard) in each of the included
studies did not meet the review question. It should be noted that the lack of concern about applicability of the three
domains mentioned above was based on the inclusion criteria set for the review. Considering the level of heterogeneity
with respect to the index test (Table 4), it appears that the judgement about applicability may be optimistic.
Findings
The key characteristics of each study are summarised in Table 3 and Table 4. The summary of main results for 16 included
studies is presented in the Summary of findings table 1.
¹⁸F-FDG PET for Alzheimer's disease dementia
We identified three studies that recruited participants from the same Alzheimer’s disease Neuroimaging Initiative
(ADNI) cohort (Herholz 2011; Landau 2010; Schmand 2012). The largest ADNI study (Herholz 2011) was included in the
analysis.
The Chételat 2003 study assessed two different discriminating brain regions (temporo-parietal and posterior cingulate). We
included data for the temporo-parietal region, since it represents a typical and 'wider' brain area that is potentially involved in
conversion to ADD.
In Pardo 2010 the PET scan was interpreted by two raters. As already mentioned, visual/qualitative reading of the ¹⁸F-FDG
PET scan is accepted as the general standard in nuclear medicine (similar to other imaging modalities). It is, therefore,
heavily dependent on the physician’s prior experience and training. The quantitative assessment plays a rather
complementary role in PET evaluations. The physician usually decides based on his or her own visual-qualitative
assessment. We included data from Reader 1 because it is very likely that Reader 1 is more experienced in interpreting brain
PET scans. This rater provided more accurate estimates of the diagnostic accuracy of Alzheimer's disease type imaging
comparing to diagnosis on follow-up.
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Individual study estimates of sensitivity and specificity are shown in Figure 4 for each of the 14 studies (150 cases and 271
non-cases) that evaluated ADD. The sensitivity values ranged from 25% to 100% while the specificity values ranged from
29% to 100%. The criteria for ¹⁸F-FDG PET positivity varied between studies. Ten studies performed PET analysis based on
the combination of visual analysis (qualitative) and rCGMr estimations (quantitative), and four studies only referred to visual
PET inspections (qualitative-only analysis). A range of different thresholds were used. The different brain regions were
studied as potential Alzheimer's disease areas as well as different scaling.
The summary ROC curve presenting the accuracy of ¹⁸F-FDG PET across the 14 studies is shown in Figure 5. Because of
the variation in thresholds and measurement of ¹⁸F-FDG uptake in brain regions, we did not estimate a summary sensitivity
and specificity. However, we derived estimates of sensitivity and likelihood ratios at fixed values of specificity from the
HSROC model we fitted to produce the summary ROC curve. At the median specificity of 82%, the estimated sensitivity was
76% (95% confidence interval (CI): 53.80 to 89.70), the positive likelihood ratio was 4.03 (95% CI: 2.97 to 5.47), and the
negative likelihood ratio was 0.34 (95% CI: 0.15 to 0.75).
In order to demonstrate whether the choice of ADNI study or discriminating brain region or reader assessment made any
differences to the pooled estimate, we performed five additional analyses. At the median specificity of 82%, the estimated
sensitivity ranged from 74% to 77%. There was no impact on our findings.
¹⁸F-FDG PET for all types of dementia (combined AD and non-AD dementia)
Five studies (64 cases and 42 non-cases) evaluated the accuracy of ¹⁸F-FDG PET for all dementia (Figure 6) in addition to
evaluating ADD. The sensitivity values ranged from 46% to 95%, while the specificity values ranged from 29% to 100%. Two
studies used a semi-quantitative threshold while the other three used visual inspection to determine test positivity. Meta-
analysis was not performed because the studies were too few and their sample sizes were too small. Figure 7 shows study
specific estimates of sensitivity and specificity in ROC space together with their 95% confidence intervals.
The estimate of sensitivity and specificity for the Pardo 2010 study was 46% and 80% for Reader 1, and 64% and 0% for the
Reader 2.
Investigation of heterogeneity 
We visually inspected the summary of ROC space (see Figure 5). The results of the included studies show a great
deal of heterogeneity. The values for both sensitivity and specificity were mainly over 80% in a number of studies (Anchisi
2005; Chételat 2003; Drzezga 2005; Fellgiebel 2007; Fellgiebel 2007; Ossenkoppele 2012a; Ossenkoppele 2012b). In
the remaining studies those values were less than 80% or a sensitivity value higher than 80% was accompanied by a
very low specificity value and vice versa (Clerici 2009; Galluzzi 2010; Mosconi 2004).
Interpretation of PET scan
There was little evidence that the HSROC model which allowed the shape, accuracy and threshold parameters to differ
between those studies using a combination of visual inspection and quantitative rCGMr evaluation interpretation and those
using visual-only interpretation provided an improvement in fit over the basic model where a single HSROC curve (Chi² = 1.7;
df = 3; P = 0.64).
Prespecifying threshold regarding rCGM
This investigation relates to the 10 studies in which semi-quantitative estimation was used. Meta-regression revealed little
evidence of an improvement in fit between the basic model and the model that allowed the parameters to differ between
those studies that did and did not specify a threshold (Chi² = 93.5 - 88.3 = 5.2; df = 3; P = 0.16).
The remaining planned investigations (for instance, the effect of the spectrum of participants, referral centres, ¹⁸F-FDG
uptake reduction brain regions, inadequate blinding or loss to follow-up) were not possible due to the limited number of
studies available for each analysis. We conducted sensitivity analyses for type of clinical diagnosis for MCI and for type of
reference standard.
Sensitivity analyses
Of the 14 studies that evaluated ¹⁸F-FDG PET for ADD, 12 used Petersen criteria for diagnosing MCI. To explore the
impact of type of diagnostic criteria on the summary estimates, we excluded two studies (Arnáiz 2001; Berent 1999) that
used the Global Deterioration Scale and AAMI respectively as the diagnostic criteria. There was no impact on our findings.
Eleven studies used NINCDS-ADRDA as the reference standard. To explore the impact of the type of reference
standard on the summary estimates, we excluded one study (Fellgiebel 2007) that used CDR = 1, one study (Herholz 2011
) that used a non-specified clinical dementia rating and the Alzheimer's Disease Assessment Scale (ADAS-cog), and
one study (Pardo 2010) where the reference standard used was not reported. There was no impact on our findings.
Discussion 
Summary of main results
For this review we identified 16 studies assessing the diagnostic accuracy of ¹⁸F-FDG PET for conversion from mild cognitive
impairment (MCI) to Alzheimer's disease dementia or to other forms of dementia. The key results are presented in Summary
of findings table 1. Due to variation in thresholds and measurement of ¹⁸F-FDG uptake in brain regions, we estimated a
summary ROC curve for studies that evaluated conversion from MCI to Alzheimer's disease dementia. We did not estimate a
summary sensitivity and specificity on the curve because with mixed thresholds a summary point lacks a clinically meaningful
interpretation. At the median specificity of 82%, the estimated sensitivity of ¹⁸F-FDG PET for conversion to Alzheimer's
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disease dementia derived from the summary ROC curve was 76% (95% confidence interval (CI): 53.80 to 89.70).
We did not pool data for the five studies that evaluated conversion from MCI to all types of dementia. The sensitivities were
between 46% and 95%, and specificities were between 29% and 100%.
¹⁸F-FDG PET for Alzheimer’s disease dementia
We identified three Alzheimer's Disease Neuroimaging Initiative (ADNI) studies (Herholz 2011; Landau 2010; Schmand
2012). ADNI is a multicentre project with approximately 50 medical centres and university sites across the United States and
Canada; it has the primary goal of evaluating magnetic resonance imaging (MRI), positron emission tomography (PET),
cerebrospinal fluid (CSF), and clinical measures acquired serially over two to three years. The aims of the three studies
differed. Herholz 2011 demonstrated the validity of ¹⁸F-FDG PET scores as an imaging biomarker for clinical trials to prevent
dementia in people with MCI. Longitudinal ADNI data showed that PET scores provide much higher test–retest reliability than
the Alzheimer's Disease Assessment Scale (ADAS-cog), which is the most frequent outcome measure used in dementia
trials. They argue that a PET scan evaluation may also provide a useful measure of disease progression, as the power for
one-year studies in people with MCI is similar to what they provide for two-year studies based on progression of ADAS-cog
scores. Landau 2010 evaluated the prognostic ability of genetic, CSF, neuroimaging, and cognitive
measurements obtained in the same participants. The authors concluded that baseline ¹⁸F-FDG PET and episodic
memory predict conversion to ADD, whereas P-tau181p/Aβ1-42 and, marginally, ¹⁸F-FDG PET predict longitudinal cognitive
decline. Schmand 2012 examined the value of neuropsychological assessment, structural MRI, CSF biomarkers, and
¹⁸F-FDG PET scanning with respect to prediction of conversion from MCI to ADD. The authors’ practical conclusions
were that these markers are not very useful, either with respect to the diagnosis of ADD beyond the age of 75, or with
respect to the prediction of conversion to ADD within a few years. In younger people, all four techniques were equally
informative, except for ¹⁸F-FDG PET, which lost its predictive potential. We created 2 x 2 tables cross-relating index test
results of the reference standard for each ADNI study. The sensitivity and specificity values vary in those studies. All
three studies used a combination of visual inspection and quantitative (rCGMr) evaluation of the PET scan, but the
threshold, brain regions, image scaling and analysis used differed between them. The number of participants with
positive ¹⁸F-FDG test at baseline also varied (Table 5). Although the samples were recruited from the same ADNI
cohort, it appears that test accuracy varies due to characteristics of the participants and index test domains. We have
included the largest ADNI study (Herholz 2011) in the analysis.
The Chételat 2003 study assessed both the temporo-parietal and posterior cingulate regions. We included data for
the temporo-parietal region. Although the posterior cingulate cortex represents the brain area in which
hypometabolism occurs in the earliest disease stage (Lucignani 2006), the bilateral temporo-parietal
hypometabolism is the standard ¹⁸F-FDG PET finding, which is also highly correlated with the pathologic diagnosis
of ADD (Hoffman 2000). Moreover, it has been suggested that hypometabolism or hypoperfusion or both in the
inferior parietal lobules are the most reliable functional indicators of progression from amnestic MCI to ADD, while
changes in the posterior cingulate cortex are most likely non-specific (Schroeter 2009).
In addition, in the Pardo 2010 study two independent blinded raters with experience in PET evaluated each image as normal
or as having an Alzheimer's disease or fronto-temporal dementia (FTD) pattern. The physicians usually based the decision
on their own visual-qualitative assessment. We therefore included data from Reader 1 because it is very likely that Reader 1
was more experienced in interpreting brain PET scans.
In order to explore whether the choice of ADNI study or discriminating brain region or reader assessment make any
differences to the pooled estimate, we performed five additional analyses. The estimated sensitivity values at the median
specificity of 82% were similar to the sensitivity value in our analysis (ranging from 74% to 77%).
In all studies ¹⁸F-FDG PET data evaluation involved qualitative (visual) assessment of the PET scans, and in some
of them this visual analysis was supported by the addition of semi-quantitative data (mainly through rCGMr
estimations), derived from quantification of brain PET images. In particular, 12 of the 16 studies applied a
combination of qualitative and quantitative assessment, while the remaining four were based only on visual data
analysis. This discrepancy introduces a degree of heterogeneity into our analysis. Moreover, and as already
mentioned, the application of different thresholds in PET studies for the specific brain area examined and the
glucose metabolism ratio applied as a threshold for discriminating a pathological from a normal scan, introduces a
further degree of heterogeneity. The use of quantification methods is not the norm in routine clinical practice.
However, their deployment has become more popular in recent years with the development of new software, which
renders quantification simpler. In general terms, there are two categories of quantification methods: the ‘traditional’
region of interest (ROI) based method, which are manually operated, and the newer voxel-based, which provide
relatively automated results. The ROI-based method has the disadvantage of being operator-dependent and
therefore time-intensive. This approach requires a high level of neuro-anatomical knowledge by the physician,
which is particularly demanding in the case of ADD, in which several specific brain areas need to be assessed. The
advent of newer voxel-by-voxel-based techniques ((like SPM (statistical parametric mapping), 3D-SSP (3D
stereotactic surface projection) and PMOD software package, which were used in the majority of the studies
involved in this meta-analysis)) that permit normalisation of brain images into a stereotactic space and are less
biased and provide higher spatial resolution than the ‘classical’ ROI-based semi-quantitative methods, increase the
physician’s diagnostic accuracy in the interpretation of a brain PET scan, leading to more reliable results (Lucignani 2006; 
Patterson 2010; Silverman 2009). In this context, the application of different quantification strategies is another factor that
could introduce heterogeneity between studies in this review.
Duration of follow-up is also important in predicting conversion to ADD. The variability in the duration of follow-up was
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considerable in the included studies (Table 4). The normal conversion rate of MCI to ADD is between 8% and 16%
per year (Mitchell 2009), but the conversion rates in our review ranged from 22% to 50%. There was a positive correlation
between follow-up time and percentage of conversion. For example, in Berent 1999, Clerici 2009 and Ossenkoppele 2012a,
the conversion rate from MCI was 50%, with the duration of follow-up ranging from two to three years. On the other
hand, the lowest conversion rates of 22% and 25% were found in the studies (Mosconi 2004; Fellgiebel 2007) with the
shortest duration of follow-up (mean 12 ± 0.6 and 19.6 ± 9.0 months respectively). Conversion rates from MCI could have
influenced the test results. However, we were not able to formally investigate the effect of duration of follow-up on the
accuracy of the ¹⁸F-FDG PET, due to a high level of heterogeneity and the small number of included studies.
We used the QUADAS-2 tool to assess methodological quality. We identified methodological issues in all the QUADAS-2
domains. Assessment of quality is dependent on adequate reporting, and QUADAS scoring was challenging because of
insufficient detail. Poor reporting about sampling procedures led mainly to an unclear risk of bias or contributed to a high risk
of bias in the participant selection domain. Although the reference standard was regarded as adequate to correctly classify
the target condition, poor reporting on blinding of dementia assessors led to an unclear risk of bias in the reference domain in
the majority of included studies.
¹⁸F-FDG PET for other forms of dementia 
We were not able to evaluate the accuracy of the index test for conversion from MCI to non-Alzheimer’s disease
dementia, due to insufficient data. Only five included studies (Clerici 2009; Galluzzi 2010; Ossenkoppele 2012a; 
Ossenkoppele 2012a; Pardo 2010) reported a small number of converters to non-Alzheimer’s dementia. Clerici 2009 and
Galluzzi 2010 reported six converters respectively (two FTD; four Lewy body dementia (LBD); six non-Alzheimer's Disease
non-specified). The remaining three studies reported only one converter each (three FTD).
As a result of the information available from these five studies, we considered the new target condition (Figure 6 and Figure
7). We did not perform meta-analysis because the studies were few and small, and there was considerable heterogeneity.
Our review therefore suggests that there is inadequate evidence available at present to address the accuracy of the ¹⁸F-FDG
PET scan to identify those people with MCI who will convert to all types of dementia (combined Alzheimer's and non-
Alzheimer's disease dementia).
Strengths and weaknesses of the review
One strength of our review is that the included studies represent probably the majority of studies about this question.
We conducted an extensive electronic search strategy, and where a study did not present all relevant data we
contacted the study authors and obtained usable data for seven studies (Anchisi 2005; Clerici 2009; Galluzzi 2010; Landau
2010; Ossenkoppele 2012a; Ossenkoppele 2012b; Schmand 2012).
Our review has some limitations. First, the clinical diagnosis of ADD or other forms of dementia is imperfect, so that the
findings from studies with post-mortem confirmation of the diagnosis are more convincing than those from studies with a
clinical diagnosis in the evaluation of the accuracy of PET imaging for the early detection of the dementia process in people
with MCI.
The findings are based on studies with poor reporting and the majority of included studies were at an unclear risk of bias,
mainly for the reference standard and for the participant selection domains. Although there was relative homogeneity in
terms of scan acquisition protocol, the process followed and the fundamental evaluation approach that people demonstrating
particular brain regions with reduced ¹⁸F-FDG uptake represent potential MCI converters to ADD, according to the
assessment of Index test domain more than 50% of studies were of poor methodological quality due to lack of a prespecified
threshold. Index tests that require subjective interpretation (such as ¹⁸F-FDG PET) are at high risk of bias for the index test
domain compared to more objective tests with widely-accepted thresholds. The Pardo 2010 study illustrates poor agreement
between both experienced raters for the correlation between diagnosis at three-year follow-up and baseline ¹⁸F-FDG PET
scans classified as PET pattern (normal, ADD, and FTD).
Due to the limited number of included studies and the meta-analytic techniques, we were unable to formally assess the
sources of heterogeneity, or to disentangle the reasons for the test accuracy results varying between studies, so even those
factors that we have been able to test cannot be excluded as reasons for the heterogeneity.
Applicability of findings to the review question
We had no concerns that the included participants and setting, the conduct and interpretation of the index test, and the
target condition (as defined by the reference standard) in each of the included studies did not address the review question:
Could ¹⁸F-FDG PET scan predict whether people with MCI would convert clinically to dementia? However, due to limited
number of included studies and levels of heterogeneity in the three domains mentioned above, it was difficult to determine to
what extent the findings from this meta-analysis can be applied to clinical practice.
Authors' conclusions 
Implications for practice 
Positron emission tomography (PET) is a unique diagnostic tool, since it can assess pathophysiologic and metabolic
processes before any anatomic changes have taken place. This capacity of PET could potentially lead to several future
applications in dementias, and generally in the field of neurosciences. ¹⁸F-FDG PET is becoming increasingly accepted in the
diagnostic approach to Alzheimer's disease and related disorders. Moreover, Silverman 2001 has developed a cost-
effectiveness algorithm for assessment of geriatric patients presenting with early symptoms of cognitive decline;
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according to this, PET can be incorporated into the diagnostic work-up of these patients, when the ‘standard’
diagnostic testing does not reveal an underlying cause for the cognitive decline (Moulin-Romsee 2005; Silverman 2001; 
Silverman 2002).
The results of the included studies show a great deal of heterogeneity, encompassing both the values which would render
the technology 'useless' and some which indicate a valuable diagnostic tool. Given the considerable variability and specificity
values, the heterogeneity in the conduct and interpretation of the test, and the lack of defined thresholds for determining test
positivity, the current evidence does not support the routine use of a ¹⁸F-FDG PET scan in clinical practice. ¹⁸F-FDG PET
scan is a high-cost investigation, and it is therefore important to clearly demonstrate its accuracy and to standardise the
process of ¹⁸F-FDG PET diagnostic modality prior to extending its use.
Implications for research 
The understanding of the functions of the nervous system and the biology of its disorders remains a big challenge. The
attempt to comprehend the molecular basis of such disorders, and to potentially interfere in the natural history of the disease,
is not driven just by theoretical or purely scientific needs. In the coming decades the number of adults over 65 years is
expected to increase dramatically. In this context, the development and application of functional diagnostic imaging
modalities that have the opportunity to detect metabolic changes before any macroscopic anatomical changes take place,
and furthermore can achieve this with the highest accuracy, will be pivotal in selecting those people who would be
candidates and would benefit most from the application of such treatments.
The ¹⁸F-FDG PET represents a modality that can reflect biochemical/molecular changes before respective
morphological imaging modalities detect them. PET assesses cerebral metabolism by measuring glucose utilisation
with the use of the radiotracer ¹⁸F-FDG, a glucose analogue, which is trapped in the neuronal cell after undergoing the
first metabolic step of phosphorylation by hexokinase. Since neuronal activity depends on the continuous supply of
energy, the assessment of glucose consumption by the cells is indicative of neuronal integrity and function. The ability
of PET to serve as a biomarker of dementia has already been highlighted (Dubois 2007; McKhann 2011). Moreover, a
recent meta-analysis demonstrated that ¹⁸F-FDG PET is the strongest individual positive predictive biomarker of short-
term incident dementia in MCI (Frisoni 2013). However, energy metabolism, reflected by ¹⁸F-FDG distribution, is not
a specific process. Neurodegenerative diseases are based on complex and overlapping molecular processes, and it
is known that the metabolic pattern particularly seen in ADD is a complicated one, resulting from neurochemical
changes, neuronal disconnection effects and neuronal cell loss, several of which are probably not detected by ¹⁸F-
FDG PET, due the non-specific nature of ¹⁸F-FDG (Hoffman 2000). Moreover, PET as a technique carries the inherent
drawback of low spatial resolution and subsequently provides anatomical information of low accuracy in comparison
with computed tomography or magnetic resonance imaging. The application of newer radiopharmaceuticals (e.g. the
PET tracer ¹¹C-PIB that specifically binds fibrillar amyloid-beta plaques), which reflect different mechanisms that
contribute to the progression from MCI to ADD and other dementias (Brück 2013), and the advent of newer hybrid
imaging modalities, like PET/MRI, that provide complementary anatomic, physiologic, metabolic, and functional
information about the brain (Catana 2012) could therefore significantly aid our understanding of brain pathophysiology,
regarding very early neurodegeneration.
Nevertheless, the results of the present analysis do not suggest the routine use of ¹⁸F-FDG PET for detection of those people
with MCI who will develop ADD. Our review carries some limitations, since generally, the methodological and reporting
quality of all considered papers was relatively poor. Therefore, future studies with more uniform approaches to thresholds,
analysis and study conduct with particular consistency in length of follow-up may provide a more homogeneous estimate
than the one that has been available from the included studies we have identified, in order to determine the exact role of ¹⁸F-
FDG PET in the diagnostic algorithm for such patients.
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Differences between protocol and review 
Investigation of heterogeneity:
We planned (New Reference) to investigate the following but these were not undertaken:
Spectrum of participants ((mean age, gender, Mini-Mental State Examination (MMSE) score, apolipoprotein (APOE) ε4
allele gene status))
Referral centres: primary care, memory clinic, and hospital
Clinical criteria of mild cognitive impairment (MCI): Petersen criteria, revised Petersen criteria, CDR = 0.5
criteria, and different MCI classification (Matthews 2008)
¹⁸F-FDG reduction regions
Image analysis techniques
Time between ¹⁸F-FDG injection and positron emission tomography (PET) acquisition
¹⁸F-FDG injection dose
¹⁸F-FDG retention detecting regions
Reference standard(s) used: NINCDS-ADRDA, DSM, and ICD10 for Alzheimer's disease dementia
Aspects of study quality, particularly inadequate blinding and loss to follow-up: consider separately those studies that have
more than 20% drop-out
Sensitivity analysis to investigate the influence of limiting permitted time between index test and dementia diagnosis on
overall diagnostic accuracy of the ¹⁸F-FDG PET biomarker.
We also planned to perform a sensitivity analysis with and without the intention-to-diagnose approach, but we were not able
to do so due to the small number of studies included.
Published notes 
Characteristics of studies
Characteristics of included studies 
Anchisi 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Consecutive sample of 67 right-handed
participants with mild cognitive impairment (Dr
Perani email on 22nd October 2013) and 41
healthy controls. We only included data on
performance of the index test to discriminate
between people with MCI who converted to
dementia and those who remained stable.
Exclusion criteria: depression and behavioural
disorders. No further information.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
67 participants with MCI, diagnosed with
the Mayo Clinical criteria (Petersen 2001) at
baseline, were recruited from 4 centres enrolled in
the Network for Efficiency and Standardisation of
Dementia Diagnosis Fifth European Framework
Research Project.
48 participants were assessed at follow-up
Gender: total sample 34 men; 33 women. MCI-non-
converters: 20M, 14F; MCI-converters: 5M; 9F;
Drop-outs: 9M, 10F
Age: total sample mean 67.7 ± 8.3; MCI-non-
converters: 65.0 ± 9.0; MCI-converters: 71.1 ± 3.9;
Drop-outs: 70.1 ± 8.3
APOEɛ4: not reported
MMSE: mean: total sample 27.7 ±1.7; MCI-non-
converters: 28.4 ± 1.1; MCI-converters: 26.6 ± 1.7;
Drop-outs: 27.2 ± 2.3 22.7 ± 11.0; Drop-outs: 29.7 ±
19.2
Education: total sample mean 11.0 ± 4; MCI-non-
converters: 11.2 ± 4.5; MCI-converters: 9.1 ± 5.0;
Drop-outs: 12.2 ± 4.8
Sources of referral: primary care physicians (Dr
Perani email on 22nd October 2013)
Sources of recruitment: outpatients from 4 University
Departments (Milan, Brescia, Cologne and Dresden)
(Dr Perani email on 22nd October 2013)
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
Studies were performed according to previously described methods (Herholz 2002). The software
packages SPM99 (Wellcome Department of Cognitive Neurology, University College, London,
England) and MATLAB 6.1 (MathWorks Inc, Sherborn, Mass) were used for image pre-processing.
Images were spatially normalised to a reference stereotactic template (Montreal Neurological Institute,
McGill University, Montreal, Quebec) by a 12-parameter transformation and smoothed by a Gaussian
kernel of 12x12x12-mm voxels full width at half maximum.
The hypometabolic regions in participants with mild cognitive impairment who developed Alzheimer's
disease compared with controls, obtained by SPM99 analysis, were used to define volume of interest
(VOI). Using only clusters > 700 voxels, 3 VOIs in the temporo-parietal regions and posterior cingulate
cortex were selected. The regional sensorimotor ¹⁸F-FDG uptake ratio (regional cerebral glucose
metabolism) was used as the index test. Sensitivity and specificity data were reported for a threshold
of 1.138, which was derived from ROC analysis.
Threshold: rCGM-r = 1.138; not prespecified
At baseline 67 MCI. A number of test+ and test- participants reported only for 48 MCI participants who
had follow-up data: 19 with positive ¹⁸F-FDG test (≤ 1.138); 29 with negative ¹⁸F-FDG test (> 1.138)
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG PET
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: median follow-up 12
months; range: 12 - 27 months
At baseline 67 MCI.
At follow-up: 48 participants: 14 MCI-ADD;
34 MCI-MCI (p 1730)
Sensitivity: 92.9%; Specificity: 82.4%; NPV:
96.55%; PPV: 68.4% (at the threshold of
rCGM-r = 1.138; p1731)
Number included in analysis: 48
TP = 13; FP = 6; FN = 1; TN = 28 (calculated
in Review Manager 5)
Loss to follow-up: 19; no further information.
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes We contacted the trial investigators who provided some additional data for the 'Patient
selection' and 'Patient characteristics and setting' items (email on 22nd October 2013).
 
Arnáiz 2001
Patient Selection
A. Risk of Bias
Patient Sampling
20 participants with MCI were consecutively
recruited from the Geriatric Clinic, Huddinge
University Hospital, Sweden
Exclusion criteria: not reported.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
20 participants with MCI, diagnosed
with the Global Deterioration Scale (Reisberg
1982) at baseline. These criteria were not
prespecified in the protocol.
Gender: Total: 8 women, 11 men; converters:
5F, 6M; non-converters: 3F, 6M
Age: converters 64.9 ± 8.3 years; non-
converters: 60.1 ± 8,4 years
APOEɛ4: not reported
MMSE: converters 26.7 ± 1.8; non-converters:
27.2 ± 2.9
Education: 11.9 ± 2.2 years; non-converters:
11.3 ± 2.0 years
Sources of referral: not reported
Sources of recruitment: Geriatric University
Hospital Clinic
Are there concerns that the included patients and setting do not match the
review question? Unclear
Index Test
Index tests
¹⁸F-FDG PET scan
The PET investigations were performed at the Uppsala University PET Center, using either of 2
scanners (GEMS 2048-15B or GEMS 4096-15WB, General Electric Medical Systems, Milwaukee, WI).
The accumulation of 2-[18F]-fuoro-deoxyglucose (¹⁸F-DFG) in the brain was followed for 60 minutes.
Regions of interest (ROIs) were defined on transaxial slices in relation to the slice where the basal
ganglia (BG) structures were best visible. Based on Herholz 1999 and Jelic 1999, rCMRGlu
were obtained for 3 regions of interest: the temporo-parietal regions 13 mm above the level
of the basal ganglia (TPabove), 13 mm below (TPbelow), and at the level of the basal ganglia (TP BG)
in the left and the right hemispheres. Estimates of the rCMGlu were standardised to the
sensorimotor area of the cortex 26 mm above the level of the basal ganglia. This region is
thought to be relatively unchanged in people with AD (Duara 1986). The rate of glucose consumption
in the brain was expressed in mol/min 3100 cm3 and calculated by a graphical method which used the
lumped constant equal to 0.418 for correction of differences in utilisation between ¹⁸F-FDG and
glucose.
Threshold: visual inspection: rCGMglc of left temporo-parietal region above the basal ganglia (Model
I); not prespecified
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: NINCDS-ADRDA
Unclear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG PET
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: average interval 36.5
months
Information from the paper 
20 MCI: 9 MCI-ADD; 11 non-converters;
baseline rCMRGlu of left TPabove (isolated)
When we used model I (left TPabove
measure isolated), the model reached a 75%
classification accuracy (P = 0.05). 3
participants with P-MCI were classified as S-
MCI and two S-MCI were classified as P-MCI
(p 853); therefore there were FN = 3; FP = 2
Calculated in Review Manager 5: TP = 6; TN =
9; sensitivity = 67%; specificity = 82%
Number included in analysis: 20
TP = 6; FP = 2; FN = 3; TN = 9
Loss to follow-up: none
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Berent 1999
Patient Selection
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A. Risk of Bias
Patient Sampling
45 participants were recruited: 18 with AD, 20
with isolated memory impairment (IMI) and 15
healthy volunteers.
Sampling procedure not described.
We only included data on performance of the
index test to discriminate between participants
with MCI who converted to dementia and
those who remained stable.
Exclusion criteria: no participants or control
subjects were taking any centrally-acting
medications at the time of study. No further
information
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
20 participants with IMI. Participants were
screened by staff of the Michigan Alzheimer’s
Disease Research Center (MADRC) and
classified using the clinical and psychometric
IMI criteria: objective and quantitative evidence
of learning inefficiency, with no evidence of
impairments in general cognitive status or
activities of daily living or behaviour due to
change in cognition. This classification is based
largely on previously published AAMI
criteria (Crook 1986), although the IMI criteria
do not require a formal memory complaint, and
there is a liberal age restriction.
Gender: 7 women; 13 men
Age: mean 70.2 ± 5.5 years
APOEɛ4: not reported
MMSE: 26.0 ± 1.9
Education: total sample average: 15 years
Sources of referral: not reported
Sources of recruitment: Cognitive Disorders
Clinic, Department of Neurology at the
University of Michigan
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
¹⁸F-FDG PETimage sets were acquired following intravenous administration of 10 mCi (370
MBq). Image sets were analysed in quantitative and non-quantitative (normalisation)
fashions described elsewhere (Minoshima 1995). Regional glucose metabolism in frontal, temporal,
parietal and occipital regions normalised to the thalamus were determined for IMI participants.
Threshold: a diagnostic index based on Z-scores of the parietal cortex was used to categorise people
with IMI into normal and abnormal CMRglc (Minoshima 1995); not prespecified
Index test was conducted before follow-up.
All tests
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: NINCDS-ADRDA;
ICD-10. All participants received both
reference standards.
Unclear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG PET
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 3 years
At baseline: 20 IMI; 10 IMI with positive
¹⁸F-FDG test; 10 IMI with negative ¹⁸F-
FDG test.
At follow-up: 10 IMI with positive ¹⁸F-FDG
test: 7 IMI-ADD; 3 IMI-IMI; 10 IMI with
negative ¹⁸F-FDG test: 3 IMI-ADD; 7 IMI-
IMI
Number included in analysis: 20
TP = 7; FP = 3; FN = 3; TN = 7
Loss to follow-up: none
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Chételat 2003
Patient Selection
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A. Risk of Bias
Patient Sampling
19 right-handed participants with a memory
complaint, but preserved activities of daily
living and 15 healthy controls were
prospectively recruited. Sampling procedure
not described.
We only included data on performance of the
index test to discriminate between people with
MCI who converted to dementia and those who
remained stable.
Exclusion criteria: neurologic, medical, or
psychiatric disorder. No further information.
People with medical disorders unrelated to
cause of memory impairment may have been
excluded.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
19 participants with MCI, diagnosed with the
Petersen 2001 criteria were recruited at baseline.
No further information. Demographic characteristics
reported on 17 MCI participants, who had a follow-
up.
Inclusion criteria: no neurologic, medical, or
psychiatric disorder; modified Hachinski score ≥ 2;
age > 55 years; education > 7 years; episodic
memory performance > 1.5 SD below age-matched
normal mean in Rey Figure delayed recall or 1
subscore of Grober-Buschke test; Neurological and
Communicative Disorders and Stroke, Alzheimer's
Disaese and related Disorders Association criteria
for Alzheimer's disease not met; MMSE ≥ 24 and
normal cognitive functions apart from episodic
memory, including the Stroop test, visuospatial
function, imitation and production of gestures, and
language.
Gender: 8 men; 9 women. MCI-non-converters: 5M,
5F; MCI-converters: 3M, 4F
Age: Total: mean 69.9 ± 6.7; MCI-non-converters:
mean 67.8 ± 7; MCI-converters: mean 73 ± 5.1
APOE 4: not reported
MMSE: ≥ 24 (no further details)
Education: not reported
Sources of referral: not reported
Sources of recruitment: not reported
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
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Index tests
¹⁸F-FDG PET scan
At entry each participant underwent an ¹⁸F-FDG PET study using the ECAT HR+ device (CTI,
Knoxville, TN). The ¹⁸F-FDG uptake datasets were handled with SPM99. SPM maps were threshold at
Z > 3.09; only decreases were assessed. 2 cerebral regions were mainly evaluated: the right temporo-
parietal and posterior cingulate. The participants were classified according to the adjusted regional
activity values in the referred areas.
Threshold: not prespecified: thresholding was set at 80% of whole brain mean of control participants.
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: NINCDS-ADRDA
criteria
Clinicians conducting follow-up were
blinded to the ¹⁸F-FDG PET results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: 18 months.
Participants were evaluated every 6 months
for an 18-month period
At baseline 19 MCI.
At follow-up: 17 participants: 7 rapid
converters (MCI-ADD); 10 non-converters
(MCI-MCI) (p 1377)
Number included in analysis: 17
TP = 7; FP = 0; FN = 0; TN = 10 (right
temporo-parietal region) (Figure, p 1376)
TP = 7; FP = 1; FN = 0; TN = 9 (posterior
cingulate region) (Figure, p 1376)
Loss to follow-up: 2 participants were
excluded post hoc: 1 refused repetitive
cognitive testing, and another turned out to
have depression (did not meet inclusion
criteria)
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Clerici 2009
Patient Selection
A. Risk of Bias
Patient Sampling
30 right-handed participants with MCI.
Sampling procedure not described. Information
from the author: 16 aMCI came from the Del
Sole 2008 study; 14 snaMCI were added to the
current study.
Exclusion criteria: i) presence of a DSM-IV
psychiatric disorder, including dementia or of
organic brain pathology or of organic illness
affecting the brain; ii) significant history of head
injury; iii) major systematic illness; iv) history of
drug and alcohol dependence; v) history of
stroke.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
30 MCI (16 aMCI and 14 snaMCI) participants were
recruited from the Department of Neurology. The
participants had experienced cognitive problems and
contacted the clinic for examination. Most of the
participants (approximately 85%) were referred by their
GPs or by a specialist, while approximately 15% came of
their own initiative. The diagnostic criteria for MCI were: 1.
Subjective and objective anamnestic evidence of
progressive cognitive impairment for more than 6 months;
2. Normal activities of daily living; 3. MMSE score of 24 or
greater; 4. a CDR score of 0.5; and 5. a score > 1.5 SD
below the mean on at least 1 cognitive dimension, as
evaluated by neuropsychological assessment.
Gender: aMCI: 10 women (62.5%) and 6 men (37.5%);
snaMCI: 10 women (71.4%) and 4 men (28.6%)
Age: aMCI: 74.92 ± 7.6 years; snaMCI: 73.62 ± 6.3 years
APOEɛ4: not reported
MMSE: aMCI: 25.82 ± 1.5; snaMCI: 26.72 ± 1.9
Education: aMCI: 9.1 ± 4.5 years; snaMCI: 8.7 ± 4.0 years
Sources of referral: GP surgeries or specialists (85%) or
self referral (15%)
Sources of recruitment: Center for Research and
Treatment of Cognitive Dysfunctions of the Department of
Neurology, University of Milan, Italy
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
An activity of 185-370 MBq of ¹⁸F-FGD, depending on person’s weight, was injected intravenously in
resting condition with eyes closed and ears unplugged; the participants were asked to rest quietly for
the next 45 minutes. The studies were performed using an ECAT ACCELL scanner (Siemens Medical
Systems, Erlangen, Germany).
PET data of MCI participants were compared to a control group of 7 cognitively normal elderly
participants described in previous study of the group (Del Sole 2008).
The aMCI and snaMCI groups were first compared to controls (as described in the Del Sole 2008
study) and then to each other on a voxel-by-voxel basis using a 2-sample t test.
Each PET study was analysed separately (according to the method described in the Del Sole 2008
study) to assess regional cerebral metabolic abnormalities in individual participants. Briefly, the SPM(t)
maps of each person were converted to binary masks, where single pixels of the images were either a
0 in areas of normal ¹⁸F-FDG uptake or 1 in areas of decreased uptake. The mask images were
summed together to generate a map of overlapping regions of metabolic impairment.
Threshold: Each scan was considered positive when a cluster of at least 100 consecutive voxel (size 2
x 2 x 2 mm³) had a metabolism lower that the control group (with P set at < 0.01 level); prespecified
(Dr Clerici email on 23rd August 2013)
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia or other
forms of dementia
Reference standard: NINCDS-ADRDA and
DSM-IV for AD dementia; McKeith criteria
for LBD; Lund and Manchester criteria for
FTD
Not clear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG PET
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: aMCI group: last follow-up
18 months; snaMCI group: follow-up at 12, 24,
and 37 months
Information from the author:
At baseline: 26 ¹⁸F-FDG+ tests; 4 ¹⁸F-FDG- tests
at baseline
At follow-up (37 months):
12 aMCI with ¹⁸F-FDG+: 11 aMCI converters (10
aMCI-ADD; 1aMCI-LBD), 1 lost to follow-up
4 aMCI with ¹⁸F-FDG-: 1aMCI-ADD; 2aMCI-MCI;
1 lost to follow-up
14 snaMCI with ¹⁸F-FDG+: 7 converters (2
snaMCI-ADD; 2 snaMCI–FTD; 3 snaMCI-LBD)
and 5 non-converters (5 snaMCI- snaMCI) and 2
lost to follow-up
Number included in analysis: 26
TP = 12; FP = 11; FN = 1; TN = 2 for Alzheimer's
disease dementia
TP = 18; FP = 5; FN = 1; TN = 2 for all forms of
dementia
Loss to follow-up: In total 4 MCI participants: 2
aMCI and 2 snaMCI. No further details.
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes We contacted the trial investigators who provided relevant data tor the 2 x 2 table to be
completed (email on 23rd August 2013).
 
Drzezga 2005
Patient Selection
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A. Risk of Bias
Patient Sampling
Prospective, consecutive recruitment of 30 participants
with MCI who were referred for diagnostic evaluation by
GPs, neurologists, psychiatrists, or other institutions.
Exclusion criteria: people who met the diagnotic criteria for
dementia or any other functional psychiatric disorder,
including major depression; symptoms of diseases or
abnormalities sufficient to cause memory impairment (e.g.
Parkinson's disease, normal pressure hydrocephalus);
major structural abnormalities on MRI (e.g. infarction, intra-
cerebral aneurysm, arteriovenous malformation); extra-
cerebral causes which could influence neuropsychological
function (e.g. use of neuroleptics, substance abuse).
The study excluded people with depression, but specified
major depression sufficient to cause memory impairment.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
30 MCI participants, diagnosed with the
Petersen 1999 and CDR 5 criteria, were
recruited from a research unit.
Baseline evaluation included medical,
psychiatric and neurological examinations
performed by an experienced psychiatrist.
Paricipants had to meet the established
diagnostic criteria for mild cognitive impairment:
subjective complaint; performance of 1.5 SD
below the age norm on the Consortium to
establish a registry for Alzheimer's Disease
(CERAD) delayed verbal recall test; CDR score
of 0.5; preserved basic activities of daily living.
Gender: 14 men; 16 women; MCI-non-
converters: 8M, 10F; MCI-converters: 6M, 6F
Age: mean: total sample 70 ± 8 years; MCI-
non-converters: 67.6 ± 8.2 years; MCI-
converters: 74.7 ± 4.7 years
APOEɛ4: MCI-non-converters: 8/18; MCI-
converters: 9/12
MMSE: MCI-non-converters: 27.6 ± 1.5; MCI-
converters: 25.9 ± 2.1
Duration of symptoms: mean 2.6 ± 2.0 years
Education: mean 11.6 ± 3.4 years
Sources of referral: GP surgeries or
neurologists or psychiatrists or other institutions
Sources of recruitment: Research Unit for
Cognitive Disorders, Technical University,
Munich, Germany.
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
¹⁸F-FDG PET scan
The index test was performed at the time of initial clinical evaluation. All participants received 370 MBq
¹⁸F-FDG at rest with the eyes closed. Participants were positioned with the head parallel to the
canthomeatal line within the gantry. 30 minutes after injection, PET was performed under standard
resting condition (eyes closed in dimmed ambient light) using a Siemens 951 R/31 PET scanner (CTI).
A sequence of 3 frames of 10 min was started and later combined into a single frame. Image data
were acquired in 2-dimensional mode with a total axial field of view of 10.5 cm and no interplane gap
space. Attenuation correction was performed by a standard ellipse-fitting method.
For analysis of the PET data, a well-established observer-independent programme
(NEUROSTAT; University of Michigan) was used to minimise observer bias. This method
has been evaluated for clinical and scientific use in people with dementia and other
cerebral disorders (Bartenstein 1997; Drzezga 1999; Ishii 2001; Minoshima 1995).
The ROIs were defined to reflect functional divisions of the cerebral lobes, and each hemisphere was
divided into the following regions: orbitofrontal, prefrontal, premotor, central, parietal superior and
inferior, occipital, temporal anterior, temporal posterior and posterior cingulate. The results from the
ROI analysis were not averaged together; each ROI was assessed individually.
The detection of significant hypometabolism (as compared with a control population) in
surface ROIs covering the posterior cingulate cortex accompanied by cortical hypometabolism
in at least unilateral temporo-parietal areas was determined as suggestive of early AD, based
on findings of earlier studies (Drzezga 2003). According to this strategy, PET baseline results were
classified as suggestive or not suggestive for AD.
Threshold: A z-score threshold of > 1.64 (1-tail) corresponding to a P value of 0.05 (1-tail)
was applied for demarcation of significant abnormalities. This statistical threshold
previously proved to be suitable for the diagnosis of DAT using the applied statistical tool (Bartenstein
1997; Minoshima 1995); prespecified.
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: NINCDS-ADRDA
criteria
¹⁸F-FDG PET results were blinded for the
later outcome of the participants, and blinded
for other clinical baseline information.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: 15 months (expanded
to a mean 16 ± 2 months)
At baseline: 30 participants: 13 with ¹⁸F-FDG
positive; 17 with ¹⁸F-FDG negative (Abstract)
At follow-up: 12 MCI-ADD; 18 MCI-MCI (p
1628); sensitivity: 92%; specificity: 89%
(Table 2, p 1629)
Number included in analysis: 30
TP = 11; TN = 16; FP = 2; FN = 1
(Calculated in Review Manager 5)
Loss to follow-up: none
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Fellgiebel 2007
Patient Selection
A. Risk of Bias
Patient Sampling
Prospective recruitment of 16 people with
aMCI, presenting at a memory clinic for
diagnostic evaluation. Sampling procedure
not described.
Exclusion criteria: people with metabolic
disease that could affect cognitive function;
people with other brain diseases; people
with a diagnosis of depression according to
DSM-IV criteria
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
16 participants, diagnosed with the Petersen
1999 criteria at baseline. 1 person in the initial
study group refused further participation and has
been replaced by a consecutively-recruited
comparable patient from the memory clinic to
preserve the statistical power for prospectively
planned follow-up analyses.
Gender: 9 men; 7 women.
Age: total sample: mean age 68.6 ± 7.9 years;
MCI-MCI: 68.8 ± 10.0 years; MCI-progressive:
68.5 ± 5.9 years (4/8 MCI-ADD: 69.5 ± 7.9 years)
APOEɛ4: not reported
MMSE: mean 25.7 ± 2.7; MCI-MCI: 27.3 ± 1.8;
MCI-progressive: 25.0 ± 2.1 (4/8 MCI-ADD: 24.3
± 1.5)
Education: not reported
Sources of referral: not reported
Sources of recruitment: University Memory Clinic,
Germany
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
Method of the index test administration described previously (Fellgiebel 2004): Acquisition was in 3D
mode . 30 minutes after injection of 180 MBq ¹⁸F-FDG, a sequence of 3 5-minute frames was started
and later combined to a single frame. Thereafter, the images were corrected for attenuation, scatter,
and dead time. Standardised 3D stereotactic surface projections for each participant, compared with a
normal database to provide Z scores.
Threshold(s): AD-typical findings were defined as significant decrease ( Z-score > 2 in more than 50
adjacent pixels) of cerebral glucose metabolism in at least 1 of the brain regions that have been shown
to be typically involved in early AD (parietal mesial or posterior cingulate and temporal regions);
prespecified.
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: Progression to
Alzheimer's disease dementia was assumed if
CDR reached 1.
Follow-up evaluation at variable time points
(not specified), comprising neurological and
psychiatric examination, CDR and MMSE.
Progressive cognitive decline was defined as
MMSE score reduction ≥ 2 and a clinical
judgement of cognitive deterioration.
Clinicians conducting follow-up were blinded to
the¹⁸F-FDG PET results.
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: Total sample: 19.6 ± 9.0
months; MCI-MCI: 19.5 ± 9.3 months; MCI-
progressive: 17.6 ± 8.8 months (4/8 MCI-ADD:
23.7 ± 2.0 months)
At baseline: 16 MCI: 7 with ¹⁸F-FDG positive; 9
with ¹⁸F-FDG negative
At follow-up: 16 MCI: 7 FDG positive: 4 MCI-
ADD, 1 MCI-MCI, 2 MCI-progressive (non-
converters); 9 FDG-: 7 MCI-MCI ; 2 MCI-
progressive (non-converters) (p 170).
Number included in analysis: 16
TP = 4; FP = 3; FN = 0; TN = 9
Sensitivity: 100%; Specificity: 75%; PPV: 57%;
NPV: 100% (calculated in Review Manager 5).
Loss to follow-up: 1/16; however, that participant
was replaced by an additional, consecutively-
recruited patient from the memory clinic.
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Galluzzi 2010
Patient Selection
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A. Risk of Bias
Patient Sampling
108 consecutive participants with MCI, referred to an
outpatient memory clinic over 24 months, were initially
selected. Finally, 90 participants were included. Of
these, only 38 underwent ¹⁸F-FDG PET scan. The
other 52 did not undergo ¹⁸F-FDG PET because of
refusal (n = 25), contraindications (n = 7) or because
they had previously undergone a brain perfusion study
with 99mTc-ECD SPECT (n = 20).
Exclusion criteria: not specified.
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
38 MCI participants with ¹⁸F-FDG scan. Diagnostic criteria
for MCI were not directly specified. However, it can be
inferred that the authors use the Petersen 1999 criteria.
MCI is defined as the presence of objective impairment in
memory or other cognitive domains (performance lower
than the 5th percentile on neuropsychological tests applied
in the study) in the absence of functional impairment.
Demographic data reported on all 90 participants included
in the study.
Gender: 53 women, 37 men
AGE: MCI-NC: 70.9 ± 7.1 years; MCI-ADD: 72.2 ± 7.1
years; MCI-non-ADD; 73.0 ± 7.1 years
APOEɛ4: MCI-NC: 19 (41%); MCI-ADD: 14 (58%); MCI-
nADD: 2 (15%). The data refer to 35 participants in total. It
is not reported how many or which of them underwent PET
scan
MMSE: MCI-NC: 26.3 ± 1.9; MCI-ADD: 26.4 ± 1 .6; MCI-
non-ADD: 25.5 ± 1.9
Education: MCI-NC: 7.7 ± 3.6; MCI-ADD: 8.8 ± 4.6; MCI-
non-ADD: 7.3 ± 4.0
Sources of referral: not reported
Sources of recruitment: Translational Outpatient Memory
Clinic (TOMC), at the National Institute for the Research
and Care of Alzheimer’s Disease (IRCCS Centro San
Giovanni di Dio Fatebenefratelli), Brescia, Italy
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
The authors did not give details regarding radiopharmaceutical (¹⁸F-FDG) administration. However,
they report on evaluation criteria applied in PET reading. As it is written in text: "FDG uptake was
assessed with the automated version (PALZ score of PMOD technologies) of the t sum score
developed by Herholz and colleagues for the diagnosis of AD, combining the virtues of voxel-based
parametric mapping with the diagnostic information on brain regions that are typically affected in AD.
Briefly, the ¹⁸F-FDG PET image of an individual patient is compared to a database of normal controls
and the voxel-by-voxel sum of t scores in an AD-pattern mask is computed. Abnormal ¹⁸F-FDG PET
was defined following the original indications of a t sum higher than 11,090" (p 2007).
Threshold: ¹⁸F-FDG PET positive: t sum > 11.090 (Herholz 2002); prespecified.
Index test was conducted before follow-up.
All tests
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia or other
forms of dementia
Reference standard: NINCDS-ADRDA
criteria
Unclear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: MCI-NC: 26.5 ± 16.0 months;
MCI-ADD: 21.5 ± 10.2 months; MCI-non-ADD: 19.1 ±
8.9 months
The data refer to all 90 people with MCI, not only to the
38 who underwent PET scan.
Information from the author:
At baseline: 28 ¹⁸F-FDG test positive; 10 ¹⁸F-FDG
negative
At follow-up: 28 with abnormal ¹⁸F-FDG PET scan: 15
MCI-converters (11 MCI-ADD; 4 MCI non-ADD) and
13 MCI-non-converters (13 MCI-MCI); 10 with normal
¹⁸F-FDG PET scan: 3 MCI-converters (3 MCI-ADD; 2
MCI-non-ADD) and 5 MCI-non-converters (5 MCI-
MCI).
Number included in analysis: 38
TP = 15; FN = 5; FP = 13; TN = 5 (conversion to All
dementia)
TP = 11; FN = 3; FP = 17; TN = 7 (conversion to ADD)
TP = 4; FN = 2; FP = 24; TN = 8 (conversion to non-
ADD dementia)
Loss to follow-up: none for 38 MCI participants with
¹⁸F-FDG scan
Lost to follow-up for the initial sample: 52 (25
participants refuse the ¹⁸F-FDG PET scan; 7 were not
performed because of contraindications and 20
because they had previously undergone 99mTc-
ECDSPECT scan).
In addition,18 participants were excluded from the
consecutive sample (N = 108): 16 due to refusal of
follow-up; 2 due to logistical problems.
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes We contacted the trial investigators who provided relevant data tor the 2 x 2 table to be
completed (email on 23rd August 2013).
 
Herholz 2011
Patient Selection
A. Risk of Bias
Patient Sampling
A subset of 94 MCI participants' baseline data,
available for all measures of interest, was used
from the ADNI, a multicentre project with
approximately 50 medical centre and university
sites across the United States and Canada.
Exclusion criteria: not reported.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
94 participants with MCI, diagnosed with the
Petersen 2010 and CDR = 0.5 at baseline,
were recruited from ADNI data.
Gender: 28 women, 66 men
Age: Total: 75.0 ± 7.6 years
APOEɛ4: not reported
MMSE: 27.1 ± 1.59
Education; not reported
Sources of referral: not reported
Sources of recruitment: multicentre
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
PET scans represented the brain activity 30 – 60 mins after injection of ¹⁸F-FDG; had been
reconstructed using 3D backprojection, 3D ordered-subset expectation maximisation, or Fourier
rebinning/2D ordered-subset expectation maximisation; were scaled to a common global average
value; and were re-oriented into a standard 160 x 160 x 96 voxel image grid (voxel size, 1.5 x 1.5 x 1.5
mm) along the anterior commissure-posterior commissure.
The AD t-sum was calculated. It indicates the severity of the metabolic decrease in those brain
areas that are typically affected by AD (multimodal association cortices mostly located in the
temporal and parietal lobes), including an adjustment for age effects. The AD t-sum was
converted into a PET score by reference to its upper limit (Herholz 2002)
ROI: temporal and parietal lobes
PET score = log2 {(ADtsum/11,089) + 1)}
Threshold: rCGMglc of t sum > 11.090 (Herholz 2002); prespecified.
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: clinical dementia
rating (not specified) and ADAS-cog
Unclear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG
results.
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
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Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 24 months
Participants were required to have had 4
¹⁸F-FDG PET scans at baseline, 6m, 12m,
and 24m.
At 24-month follow-up: 30 MCI-ADD, 64
MCI-non-convertors (57 MCI-MCI; 7 MCI-
normal cognition); sensitivity = 57%;
specificity = 67% (p 1220)
45% abnormal ¹⁸F-FDG tests (Table 2, p
1220): 38 test positive; 56 test negative
Number included in analysis: 94
TP = 17; FP = 21; FN = 13; TN = 43
(Calculated in Review Manager 5)
Loss to follow-up: none
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Landau 2010
Patient Selection
A. Risk of Bias
Patient Sampling
Retrospective analysis of 85 people with MCI
taken from a larger study. Participants had MCI
and baseline data were available for all
measures of interest to the current study.
No exclusion criteria were specified.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
85 participants with MCI (Petersen 2010 and
CDR = 0.5 criteria), whose data were analysed,
were recruited from the ADNI, a multicentre
project with approximately 50 medical centre and
university sites across the United States and
Canada. Approximately 200 cognitively normal
older participants, 400 participants with MCI, and
200 with early AD are enrolled in ADNI, all of
whom have had MRI scanning; approximately
50% have had PET scanning, and approximately
50% also agreed to lumbar puncture.
MCI participants were classified as
single-domain or multi-domain amnestic
MCI (Petersen 2003).
Gender: 56 men; 29 women. MCI-non-
converters: 37M, 20F; MCI-converters: 19M, 9F
Age: MCI-non-converters: mean 78 ± 7.4 years;
MCI-converters: mean 78.3 ± 7.5 years
APOEɛ4: MCI-non-converters: 14 (25%); MCI-
converters: 11 (41%)
MMSE: MCI-non-converters: mean 27.3 ± 1.6;
MCI-converters: mean 26.4 ± 1.7
Education: MCI-non-converters: mean 16.3 ± 2.8;
MCI-converters: mean 16.4 ± 2.6
Sources of referral: not reported
Sources of recruitment: multicentre
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
PET images were acquired 30 – 60 minutes post-injection. Images were averaged, spatially aligned,
interpolated to a standard voxel size, intensity normalised, and smoothed to a common resolution of 8
mm full width at half maximum. Spatial normalisation of each individual’s PET volume to the standard
¹⁵O-H₂O PET template was conducted using SPM5 (template voxel dimensions: 91 x 109 x 91; voxel
size: 2 mm x 2 mm x 2 mm).
The regions of interest selected were study-independent, frequently associated with decline in AD and
MCI (no further details). Optimal diagnostic thresholds were derived from a ROC analysis.
Threshold: 1.21 (Table 2 – most likely this value refers to rCMRglc); not prespecified.
The mean ± SD values on ¹⁸F-FDG scan are referred on Table 1: MCI-non-converters: 1.22 ± 0.14;
MCI-converters: 1.13 ± 0.10
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to Alzheimer's
disease dementia
Reference standard: NINCDS-ADRDA criteria.
Cognitive decline was measured by
ADAS–Cognitive Subscale (Rosen 1984) and
standard diagnostic criteria.
Unclear whether clinicians conducting follow-up were
aware of the ¹⁸F-FDG results.
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 1.9 ± 0.4 years;
maximum 3 years
Follow-up occurred at multiple time points (6,
12, 18, 24 and 36 months)
At baseline 85 participants with MCI.
At follow-up: 85 participants: 28 MCI-ADD;
57 MCI-MCI (p 232)
Information from the author:
At follow-up: 51 MCI with positive ¹⁸F-FDG
biomarker: 21 MCI-ADD, 30 MCI-MCI; 34
MCI with negative ¹⁸F-FDG biomarker: 7
MCI-ADD, 27 MCI-MCI
Number included in analysis: 85
TP = 21; FP = 30; FN = 7; TN = 27
Loss to follow-up: none; all 85 participants
appear to have been included in the
analysis.
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes We contacted the trial investigators who provided relevant data tor the 2 x 2 table to be
completed (email on 24th January 2013).
 
Mosconi 2004
Patient Selection
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A. Risk of Bias
Patient Sampling
People with aMCI, recruited over a 2-year period.
Sampling procedure not described.
Exclusion criteria: major psychiatric or medical
disease; using medication that could affect brain
structure or function (previous subarachnoid or
intra-cerebral haemorrhage, intra-cranial tumour,
hydrocephalus, psychosis, major depression,
alcoholism, epilepsy, ischaemic stroke, vascular
dementia and other dementing illnesses, anaemia,
untreated thyroid dysfunction, renal insufficiency,
non-stabilised diabetes mellitus).
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
37 MCI participants, diagnosed with the Petersen
2001 criteria at baseline.
Gender: converters: 5 women; 3 men; non-
converters: 15 women; 14 men
Age: converters: 69 ± 4 years; non-converters: 63 ±
8 years
APOEɛ4: total: APOE4(+)16; APOE4(-) 21.
APOE4(+) MCI-non-converters: 11/16; APOE4(+)
MCI-converters: 5/16; APOE4(-) MCI-non-
converters: 18/21; APOE4(-) MCI-converters: 3/21
MMSE: MCI-non-converters: 28.1 ± 1.6; MCI-
converters: 23.9 ± 1.7
Education: MCI-non-converters: 10.0 ± 5.0; MCI-
converters: 8.0 ± 3.0
Sources of referral: not reported
Sources of recruitment: not reported. The
recruitment was carried out according to the
general protocol of the Network for Efficiency
and Standardisation of Dementia Diagnosis
research project (Herholz 2002).
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
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Index tests
¹⁸F-FDG PET scan
PET scans were performed using GE Advance PET devices (Milwaukee, WI). Scans were acquired in
2D mode with an axial field of view of 153 mm, an in-plane full width at half-maximum (FWHM) of 4.6
mm, and slice thickness of 4.25 mm. Participants were injected with a dose of 110 to 370 MBq of [¹⁸F]
FDG in a resting state with eyes closed and ears unplugged in a dimly-lighted room with minimal
background noise. A polycarbonate head holder was used to reduce head movement during the scan.
The uptake interval between FDG injection and scan start was on average 42 ± 19 minutes. The
average scan duration was 19 ± 3 minutes. Images were reconstructed using filtered back-projection
including correction for attenuation measured by transmission scan and scatter using standard
software as supplied by scanner manufacturers.
Basic image processing and voxel-based data analyses were performed using SPM99 routines
(Wellcome Department of Cognitive Neurology, London, UK) implemented in MATLAB (Mathworks,
Sherborn, MA). An isotropic Gaussian filter was used to smooth the spatially normalised PET images
with an FWHM of 12 mm. Individual counts were normalised to mean global activity using proportional
scaling to obtain relative cerebral metabolic rate for glucose (rCMRglc) values from FDG radioactivity
measurements. To minimise 'edge effects' without excluding hypometabolic tissue, only those voxels
with values > 80% of the mean for the whole brain were retained for all statistical analyses. Global
calculation was obtained with respect to the mean voxel value.
The writers defined the precuneus (PreCu), anterior (ACC), and posterior (PCC) cingulate cortex,
inferior parietal lobule (IPL), superior (STG) and middle (MiTG) temporal gyrus, and superior (SFG),
middle (MiFG), and inferior frontal (IFG) gyrus, on both hemispheres, as candidate areas for possible
rCMRglc alterations.
Threshold: no specific rCMRglc value is referred as threshold. The writers characterise a PET scan as
positive or negative for significant rCMRglc reductions in certain cerebral areas with emphasis on the
inferior parietal lobule (IPL). No threshold or related quantitative data are provided.
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: NINCDS-ADRDA
criteria
Clinicians conducting follow-up were
blinded to APOE results. Unclear whether
they were unaware of the ¹⁸F-FDG results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: mean 12.1 ± 0.6 months
At baseline 37 MCI.
At follow-up: 37 participants: 8 MCI-ADD; 29 MCI-MCI
(p 2335)
Sensitivity: 38%; Specificity: 97% (p 2336)
Number included in analysis: 37 
TP = 3; FP = 1; FN = 5; TN = 28 (calculated in Review
Manager 5)
Loss to follow-up: none
All participants appear to have been included in the
analyses (conversion/non-conversion outcomes were
reported for 37 participants).
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes Additional information were requested from the trial investigators regarding the
threshold but no further information was available at the time this review was prepared
(email on 5th September 2013)
 
Nobili 2008
Patient Selection
A. Risk of Bias
Patient Sampling
36 participants with memory complaints in whom an
objective memory deficit was demonstrated by means of
neuropsychological tests and 17 healthy volunteers who
gave their informed consent were recruited during
university courses dedicated to elderly people. Sampling
procedure not described. We only include data on
performance of the index test to discriminate between
people with MCI who converted to dementia and those
who remained stable.
Excusion criteria: presence of analphabetism, major vision
disturbances, psychiatric illnesses, epilepsy, major head
trauma, Parkinsonism, previous stroke or TIA and brain
masses; people scoring higher than 0 on the delusion and
the hallucination NPI items were excluded.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
36 participants with MCI, diagnosed with the
Petersen 2004 criteria at baseline, were recruited
from the Outpatient clinic. Demographic
characteristics are reported for 33 participants
who were included in the analysis.
Gender: converters: 11 women, 11 men; non-
converters: 9 women, 2 men
Age: converters: 77.3 ± 4.8 years; non-
converters: 74.6 ± 5.4 years
APOEɛ4: not reported on all MCI participants.
converters: 4/8 (50%); non-converters: 5/14
(36%)
MMSE: converters: 27.6 ± 1.4; non-converters:
27.4 ± 2.0
Education: converters: 8.5 ± 3.9; non-converters:
8.8 ± 4.7
Sources of referral: not reported
Sources of recruitment: outpatients, no further
information
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
The index test was performed within 3 months from the clinical–neuropsychological
examination (mean 29.9 days in participants and 29.8 days in controls). Participants fasted
for at least 6 hours. Before radiopharmaceutical injection, blood glucose was checked and
was < 140 mg/dl in all cases. After a 10-min rest in a silent and obscured room, with eyes
closed and ears unplugged, participants were injected with approximately 370 MBq of ¹⁸F-
FDG PET via a venous cannula, according to the guidelines of the European Association of
Nuclear Medicine (Bartenstein 2002). They remained in the room for 30 mins after injection, and were
then moved to the PET room where scanning started approximately 45 mins after injection and lasted
20 mins.
Threshold: not reported; visual interpretation - 25 VROI (volumetric region of interest).
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia
Reference standard: NINCDS-ADRDA;
DSM-IV. All participants received both
reference standards.
Unclear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean 21.1 ± 10.9
months; mean 20.6 ± 10.3 MCI/MCI; mean
22.2 ± 12.4 MCI/ADD
At baseline: 36 MCI
At follow-up: 11 converters; 22 non-
converters (Abstract)
Number included in analysis: 33
TP = 9; FN = 2; TN = 20; FP = 2 (Table 4, p
2197).
Sensitivity: 82%; specificity: 91% (calculated
in Review Manager 5)
Loss to follow-up: 3 participants
excluded from the analysis: 2 no
longer showed any cognitive
objective deficit after 26 and 35
months, respectively, and were
excluded from the study. Another
participant developed fronto-
temporal dementia, according to the
current criteria (Knopman 2005) after 1 year
and was excluded.
Was there an appropriate interval between index test and reference
standard? No
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
Ossenkoppele 2012a
Patient Selection
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A. Risk of Bias
Patient Sampling
At baseline 15 participants were included in each
group: MCI, AD and controls. No further details of
participant sampling and recruitment were
reported.
We only included data on performance of the
index test to discriminate between people with
MCI who converted to dementia and those who
remained stable.
Exclusion criteria were a history of major
psychiatric or neurological illness (other than AD)
and the use of nonsteroidal anti-inflammatory
drugs. People with severe vascular events during
the follow-up period, such as stroke or
haemorrhage, were also excluded.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
15 participants diagnosed by the Petersen
1999 criteria. Data reported only on 12 MCI
participants.
Gender: 9 men; 3 women
Age: mean 67 ± 7 years
APOE ε4 carrier: 8
MMSE: 27 ± 3
Education: median (range): 6 (3 - 7) years
Sources of referral: not reported.
Sources of recruitment: not reported.
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
150 ± 17 MBq ¹⁸F-FDG was injected at baseline, and 35 mins later, a 10-min transmission scan (3 x 5-
min frame) were performed. For regional analysis SUVr of the frontal, parietal and lateral temporal
cortices, and the medial temporal lobe and posterior cingulate were calculated.
Threshold: visual inspection. Threshold (SUVr of ROI) not reported
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia or other
forms of dementia
Reference standards: NINCDS-
ADRDA criteria for AD (McKhann 1984);
Reference standard for the clinical criteria
for FTD not reported.
Unclear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG
results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean interval 2.5
years (range 2 - 4 years)
At baseline: 15 MCI participants. Data
reported only on 12 MCI participants: 4 FDG
positive test; 8 FDG negative test (from the
author).
At follow-up: 12 participants: 5 MCI-
converters (4 MCI-ADD; 1 MCI-FTD); 8 MCI-
non-converters MCI (8 MCI-MCI) (from the
author).
Number included in analysis: 12
Conversion from MCI to ADD:
TP = 3; FP = 1; FN = 1; TN = 7
Conversion from MCI to all dementia:
TP = 3; FP = 1; FN = 2; TN = 6
Loss to follow-up: 3 MCI patients refused to
participate in the follow-up study due to lack
of motivation
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Low risk
Notes
Notes We contacted the trial investigators who provided the relevant data tor the 2 x 2 table
to be completed and confirmed there are no overlapping participants with the
Ossenkoppele 2012b study (email on 25th July 2013).
 
Ossenkoppele 2012b
Patient Selection
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A. Risk of Bias
Patient Sampling
154 participants included from the outpatient
memory clinic of for assessing the impact of
molecular imaging on the diagnostic process.
Among those participants there were 30
people with MCI. No further details of
participant sampling and recruitment were
reported.
We only include data on performance of the
index test to discriminate between people with
MCI who converted to dementia and those
who remained stable.
Exclusion criteria: major clinical and
psychiatric disorders, recent vascular events
and excessive substance abuse.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
30 MCI participants diagnosed by the
Petersen 2001 criteria at baseline.
Gender: 23 men; 7 women
Age: 64 ± 9
APOE ε4 carrier: not reported
MMSE: 27 ± 2
Education: not reported
Sources of referral: not reported
Sources of recruitment: Outpatient Memory
Clinic,the VU University Medical Centre, The
Netherlands.
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
Threshold: visual inspection. Threshold (SUVr of ROI) not reported.
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia or other
forms of dementia
Reference standards: NINCDS-
ADRDA criteria for ADD (McKhann 1984);
Reference standard for the clinical criteria
for FTD not reported.
Reference standards performed both with
and without the index test results on the
total sample. Unclear whether the data
reported on 12 participants relate to the
reference standards performed with or
without the index test results.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: 2 years
At baseline: 30 MCI: 15 FDG positive test;
15 FDG negative test (Table 1, p 4)
At follow-up: 12 participants: 7 MCI-
converters (6 MCI-ADD; 1 FTD); 5 MCI-non-
converters MCI (5 MCI-MCI) (from the
author)
Number included in analysis: 12
Conversion from MCI to ADD:
TP = 5; FP = 0; FN = 1; TN = 6
Conversion from MCI to all dementia:
TP = 5; FP = 0; FN = 2; TN = 5
Loss to follow-up:18 MCI participants. No
further information.
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes We contacted the trial investigators contacted who provided relevant data tor the 2 x 2
table to be completed and confirmed there are no overlapping participants with the
Ossenkoppele 2012a study (email on 25th July 2013)
 
Pardo 2010
Patient Selection
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A. Risk of Bias
Patient Sampling
19 MCI participants and 27 healthy controls
underwent extensive medical and laboratory
examination. The controls were recruited from
the community. Sampling procedure not
described. We only include data on
performance of the index test to discriminate
between participants with MCI who converted
to dementia and those who remained stable.
Exclusion criteria: not reported.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
19 MCI participants with MCI, diagnosed by
the Petersen 1999 criteria at baseline.
Gender: not reported
Age: mean 80 years; range: 54 - 83 years
APOEɛ4: not reported
MMSE: not reported
Education: not reported
Sources of referral: not reported
Sources of recruitment: Memory loss clinic,
Geriatric, Research, Education, and Clinical
Center, the Minneapolis Veterans Affairs
Medical Center MVAMC) in Minneapolis, USA
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
Participants received an intravenous injection of ¹⁸F-FDG at a dose of 5 mCi/70 kg, as they reclined
with eyes closed and ears open in a quiet dark room. After a 30-min uptake period, they were
transferred to an ECAT 953B or ECAT Exact scanner (Siemens, Knoxville, TN). Attenuation was
measured. No arterial catheters were used for absolute quantitation.
Baseline PET scan analysis was performed visually independently by two blinded, experienced
physicians. The readers characterised the scans as normal or abnormal (if abnormal, ADD or FTD
pattern). The patterns on which the PET readers characterised the scans as ADD or FTD are
described in detail in the paper (p 328, paragraph 2.3).
Also in 13 MCI cases and 15 controls, a computerised classifier (SVM) was applied. Using this
method, 2 features were defined: lobe and cluster.
Threshold: visual interpretation; threshold not prespecified.
The only thresholds applied were those used for SVM analysis: Based on the lobar features, a brain
lobe was labelled as MCI or normal if ≥ 50% of the cubes had the label MCI or normal respectively.
The cluster feature used a template based on the average image of the MCI participants. Each cluster
or connected region was identified by using a t threshold of 2.
Index test was conducted before follow-up.
The readers of the PET scan were blinded to each other's opinions.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
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B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to
Alzheimer's disease dementia or other
forms of dementia (FTD and LBD).
Reference standard: not reported.
Unclear whether clinicians conducting
follow-up were aware of the ¹⁸F-FDG
results.
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow-up: 3 years
At follow-up: JVP characterised the baseline
PET scans of the 19 MCI participants as: 6
ADD, 1 FTD, 11 HC (healthy control), 1 artefact
(non-diagnostic). In summary: 7 PET (+)
participants, 11 PET (-) participants, 1 non-
diagnostic (for all forms of dementia); MAK
characterised the baseline PET scans of the 19
MCI participants as: 10 ADD, 1 ADD/FTD, 3
FTD, 5 HC. In summary: 14 PET (+)
participants, 5 PET (-) participants (for all forms
of dementia).
Number included in analysis: 18 participants for
JVP Note: The participant with ‘artefact’ PET
scan not included; 19 participants for MAK.
1) Conversion from MCI to ADD (Table 2, p
331).
Reader1 (JVP) 
At follow-up: TP = 2; FP = 4; FN = 6; TN = 6
Reader2 (MAK):
At follow-up: TP = 3; FP = 7; FN = 6; TN = 3
Note: The PET scan read as ADD/FTD by MAK
was accounted as index test (-)
2) Conversion from MCI to any form of dementia
(Table 2, p 331)
Reader1 (JVP)
TP = 6; FP = 1; FN = 7; TN = 4
Reader2 (MAK)
At follow-up: TP = 9; FP = 5; FN = 5; TN = 0
Note: The PET scan read as ADD/FTD by MAK
was accounted as index test (+)
Loss to follow-up: none
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Unclear
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Schmand 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
175 MCI participants’ data, available for all
measures of interest, were used from ADNI, a
multicentre project with approximately 50 medical
centre and university sites across the United
States and Canada. Sample procedure was not
described for the study participants.
Exclusion criteria: people who used antidepressant
medications with anti-cholinergic properties, or
those who used drugs with narcotic properties
were excluded, but use of oestrogens,
cholinesterase inhibitors, or vitamin E was allowed
if the dose remained stable.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
89 MCI ADNI participants diagnosed by the
Petersen 2010 criteria who had a ¹⁸F-FDG scan
at baseline. Demographic data reported on total
sample (175 MCI).
Gender: converters: 31 women, 50 men; non-
converters: 30 women, 64 men
Age: converters: 74.4 ± 7.4; non-converters:
74.1 ± 7.6
APOEɛ4: not reported
MMSE: converters: 26.6 ± 1.8; non-converters:
27.2 ± 1.7
Education: converters: 15.6 ± 3.0; non-
converters: 15.8 ± 3.9
Sources of referral: not reported
Sources of recruitment: multicenter
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
¹⁸F-FDG PET scan
Using ¹⁸F-FDG acquired, controlled, and analysed according to the ADNI protocol, ROI
approaches (UC Berkeley) resulted in a set of 5 regions located in right and left angular gyri,
bilateral posterior cingulate gyrus, and left middle/inferior temporal gyrus. Because these ROIs
were highly correlated (Jagust 2010), we averaged them across participants. This composite ROI was
used in the present analyses.
Threshold: was based on the predicted probability of conversion to dementia as obtained from a
logistic regression analysis with conversion as dependent variable and the rCGM of the ROI,
described in the paper as the predictor. If this predicted probability was > 0.5, the ¹⁸F-FDG was
considered positive. This corresponds to a rCGM value of < 1.20; prespecified (Dr Schmand email on
13th August 2013).
Index test was conducted before follow-up.
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: conversion from MCI to Alzheimer's
disease dementia
Reference standard: NINCDS/ADRDA criteria of
probable ADD (including a MMSE score between 20
and 26, and a CDR score of at least 0.5).
Unclear whether clinicians conducting follow-up were
aware of the ¹⁸F-FDG results.
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow-up: mean: 2.7 ± 0.9
years; range: 0.5 - 4.6 years
Information from the author:
At baseline: 18 participants with ¹⁸F-FDG
test positive tests; 71 participants with ¹⁸F-
FDG negative tests
At follow-up: 18 with abnormal ¹⁸F-FDG
PET scan: 9 MCI-converters (MCI-ADD)
and 9 MCI-non-converters (MCI-MCI); 71
with normal ¹⁸F-FDG PET scan: 29 MCI-
converters (MCI-ADD) and 42 MCI-non-
converters (MCI-MCI)
Number included in analysis: 98
TP = 9; FP = 9; FN = 29; TN = 42
Loss to follow-up: none
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes We contacted the trial investigators contacted who provided relevant data tor the 2 x 2
table to be completed (email on 13th August 2013)
 
Footnotes
AD: Alzheimer's disease
ADAS: Alzheimer's Disease Assessment Scale
ADD: Alzheimer's disease dementia
APOE ?4: apolipoprotein ε4 allele gene status
CDR: clinical dementia rating
FN: false negatives
FP: false positives
FTD: fronto-temporal dementia
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IMI: isolated memory impairment
LBD: Lewy body dementia
MCI: mild cognitive impairment
MCI-ADD: People with MCI converted to ADD) (MCI converters)
MCI-MCI: People with stable MCI (MCI non-converters)
MCI-NC: People with stable MCI (MCI non-converters)
MMSE: mini-mental state examination
aMCI: amnestic MCI
sna-MCI: single-non-amnestic MCI
P-MCI: progressive MCI
ROI: region of interest
S-MCI: stable MCI
SUVr: standardised uptake value ratio
SVM: support vector machine
NPV: negative predictive value
PPV: positive predictive value
TN: true negatives
TP: true positives
Characteristics of excluded studies 
Bastin 2010
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators.
Study design: threshold not used (Author's email on 14th August 2012)
 
Beckett 2010
Reason for exclusion Study design: threshold not used. The focus of the study was to compare annual
changes in rCMRglc levels between MCI converters and MCI non-converters at follow-
up (ADNI study).
 
Charil 2011
Reason for exclusion Study design: threshold not used. The focus of the study was to investigate annual
changes in FDG-PET scans in different study groups (ADNI study).
 
Chen 2010
Reason for exclusion Target condition: not conversion from MCI to dementia.
Study design: threshold not used. The focus of the study was the measurement of the
cerebral metabolic rate for glucose over a 12-month period (ADNI study).
 
Chételat 2001
Reason for exclusion Study design: threshold not used. The focus of the study was to statistically compare
initial PET data of people who developed ADD to those who did not at follow-up.
 
Chételat 2005
Reason for exclusion Target condition: not conversion from MCI to dementia.
Study design: threshold not used. The focus of the study was the measurement of the
cerebral metabolic rate for glucose and comparison between that measurement and
neuropsychological assessment in predicting global cognitive deterioration in people
with MCI over an 18-month period.
 
Desikan 2010
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Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
Study design: threshold not used (ADNI study).
 
Drzezga 2003
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
Study design: threshold not used. The focus of the study was to evaluate changes in
the baseline and follow-up ¹⁸F-FDG-PET scans.
 
Forsberg 2008
Reason for exclusion Study design: threshold not used. The focus of the study was to compare rCMRglc
levels between MCI converters and MCI non-converters at follow-up.
 
Garibotto 2008
Reason for exclusion Study design: threshold not used. The focus of the study was to assess education and
occupation as proxies for reserve in aMCI converters.
 
Gray 2012
Reason for exclusion Study design: threshold not used. The focus of the study was to investigate the value
of combining cross-sectional and longitudinal multi-region FDG-PET information for
classification of Alzheimer's disease (ADNI study).
 
Hunt 2007
Reason for exclusion Study design: threshold not used. The focus of the study was to compare rCMRglc
levels between MCI converters and MCI non-converters at follow-up.
 
Ishii 2009
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
Study design: threshold not used. The focus of the study was to compare rCMRglc
levels between MCI converters and MCI non-converters at follow-up.
 
Ishii 2011
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Jagust 2007
Reason for exclusion Target condition: not conversion from MCI to dementia.
Study design: threshold not used.
 
Kadir 2012
Reason for exclusion Study design: threshold not used. The focus of the study was to examine dynamic
changes in FDG imaging at different stages of Alzheimer's disease.
 
Kawashima 2012
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Reason for exclusion Study design: threshold not used. The focus of the study was to examine the
association between baseline profiles and risk of early conversion to ADD (ADNI
study).
 
Kim 2010
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators.
Study design: threshold not used (Author's email on 4th October 2013)
 
Landau 2011
Reason for exclusion Study design: threshold not used. The focus of the study was to assess annual
changes in biomarkers (ADNI study).
 
Landau 2012
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Lee 2011
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Lo 2011
Reason for exclusion Target condition: not conversion from MCI to dementia.
Study design: threshold not used. The focus of the study was to investigate rates of
change in level of FDG uptake (ADNI study)..
 
Lo 2012
Reason for exclusion Target condition: not conversion from MCI to dementia.
Study design: threshold not used. The focus of the study was to investigate the
vascular contribution to longitudinal changes of rCMRglc in MCI and ADD participants
(ADNI study).
 
Lorenzi 2010
Reason for exclusion Target condition: not conversion from MCI to dementia.
Study design: threshold not used. The focus of the study was to assess the benefit of
the enrichment of MCI participants with true Alzheimer's disease cases by means of
¹⁸F-FDG-PET scan and other biomarkers (ADNI study).
 
Lucidi 2012
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Morbelli 2010
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Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
Study design: threshold not used. The focus of the study was to concurrently
investigate patterns of hypometabolism and athrophy in people with aMCI converted to
ADD.
 
Morbelli 2012
Reason for exclusion Study design: threshold not used. The focus of the study was to explore resting-state
metabolic connectivity in people with aMCI who converted to ADD at follow-up.
 
Pagani 2010
Reason for exclusion Study design: threshold not used. The focus of the study was to test the hypothesis
that the combination of memory and brain metabolic assessment could identify
subgroups of those MCI who would convert or would not convert to dementia at follow-
up.
 
Small 1995
Reason for exclusion Study design: threshold not used. The focus of the study was to investigate predictors
of cognitive changes in middle-aged and older adults with memory loss.
 
Torosyan 2011
Reason for exclusion Insufficient data to complete 2 x 2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
 
Walhovd 2010
Reason for exclusion Study design: threshold not used. The focus of the study was to combine FDG-PET,
MRI and CSF biomarkers in the 2-year prognosis of MCI and Alzheimer's disease
participants (ADNI study).
 
Zhang 2012
Reason for exclusion Insufficient data to complete 2X2 table. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared.
Study design: threshold not used. The focus of the study was to assess the predictive
value of longitudinal and multimodal biomarkers in conversion from MCI to ADD (ADNI
study).
 
Footnotes
ADD: Alzheimer's disease dementia
ADNI: Alzhiemer's disease neurimaging initiative
CSF: cerebro-spinal fluid
MCI: mild cognitive impairment
MRI: magneitc resonance imaging
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Summary of findings table
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What is the diagnostic accuracy of ¹⁸F-FDG PET biomarker for detecting Alzheimer's disease, and predicting progression to
dementia, in people with mild cognitive impairment
Descriptive 
Participant
population
Participants diagnosed with MCI at baseline using any of the Petersen criteria or CDR = 0.5 or any 16
definitions included by Matthews 2008
Sources of
referral
 
GP surgeries or specialists or other institutions or self referral (n = 3)
Not reported (n = 13)
MCI criteria  
Petersen criteria (with or without CDR = 0.5 criterion) (n = 14)
AAMI criteria (n = 1)
Global Deterioration Scale (n = 1)
Sampling
procedure
 
Consecutive or random (n = 3)
Unclear (n = 13)
Prior testing The only testing prior to performing the ¹⁸F-FDG PET scans was the application of diagnostic criteria for
identifying participants with MCI
Sources of
recruitment
 
University departments, clinics or research centres (n = 7)
Multicentre, not specified (n = 3)
Outpatient memory clinic or outpatients (sources not specified) or Geriatric, Research, Education and
Medical centre (n = 3)
Not reported (n = 3)
Index tests ¹⁸F-FDG PET
Threshold
prespecified at
baseline
 
Yes (n = 6)
No (n = 10)
PET scan
interpretation
 
Combination of visual inspection and quantitative (rCGMr) evaluation (n = 12)
Only visual PET scan interpretation (n = 4)
Threshold Almost all included studies referred to ratios of cerebral glucose metabolism (rCGMr) and not to absolute
numbers. They used a range of different thresholds (different brain regions studied as potential AD areas
as well as different scaling).
Most of the studies (12/16) performed PET analysis based on the combination of visual analysis
(qualitative) and rCGMr estimations (quantitative). The rest (4/16) only referred to visual PET inspections
(qualitative-only analysis).
¹⁸F-FDG
hypometabolism
regions
Authors used brain regions that are expected to be affected by AD. In these terms, all studies involved
temporo-parietal lobes and most of them (12/16) also included the posterior cingulate metabolism in their
assessment. 7 studies also involved part of the frontal lobes in their evaluations.
Reference
standard
For Alzheimer’s disease dementia:
NINCDS-ADRDA (n = 13)
Other (n = 3)
Target condition Conversion from MCI to Alzheimer’s disease dementia or any other forms of dementia.
Included studies Prospectively well-defined cohorts with any accepted definition of MCI (as above). 16 included
studies (N=697 participants) were identified. 3 studies included ADNI participants. Number included in
analysis was 421 from 14 studies.
Quality concerns QUADAS-2 scoring was challenging due to insufficient details. Poor reporting about sampling procedure
led mainly to unclear risk of bias or contributed to high risk of bias in the participant selection domain.
Although the reference standard was regarded as adequate to correctly classify the target condition, poor
reporting on blinding of dementia assessors determined unclear risk of bias in the reference domain in
most of the included studies. According to the assessment of Index test domain, more than 50% of
studies were of poor methodological quality due to lack of prespecified threshold.
Limitations Limited investigation of heterogeneity due to insufficient number of studies. Lack of common thresholds.
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Test Studies Cases/
Participants
Median specificity
from included
studies
Sensitivity 
(95% CI)1 at
median specificity 
Consequences in a cohort of 1000
Median percentage
converting % (range)2
Missed
cases3
Over
Diagnosed3
Alzheimer's disease dementia
¹⁸F-FDG
PET
14 150/421 82 76 (54 to 90) 38.5 (22 - 50) 174 285
 
Key feature of the results:
The results of the included studies show a great deal of heterogeneity, encompassing both values which would render the
technology “useless” and some which indicate a valuable diagnostic tool. The sensitivity values ranged from 25% to 100%,
while the specificity values ranged from 29% to 100%. The values for both sensitivity and specificity were mainly over 80%
in 7 included studies. In the remaining 7 studies those values were less than 80% or a sensitivity value higher than 80%
was accompanied by a very low specificity value and vice versa.
Investigation of heterogeneity:
We investigated the effects of interpretation of PET scan (combination of visual inspection and quantitative rCGMr
evaluation versus those that used visual interpretation only) and use of the prespecified threshold on the test results. There
was no impact on our findings.
The remaining planned investigations (e.g. the effect of spectrum of participants, referral centres, ¹⁸F-FDG reduction brain
regions, inadequate blinding or loss to follow-up) were not possible due to the limited number of studies available for each
analysis. We conducted sensitivity analyses for type of clinical diagnosis for MCI and for type of reference standard. There
was no impact on our findings.
Conclusions:
Given the considerable variability and specificity values, the heterogeneity in the conduct and interpretation of the test, and
lack of defined thresholds for determination of test positivity in the included studies, the current evidence does not support
the routine use of ¹⁸F-FDG PET scan in clinical practice. ¹⁸F-FDG PET scan is a high-cost investigation, and it is therefore
important to clearly demonstrate its accuracy and to standardise the process of ¹⁸F-FDG PET diagnostic modality prior to its
being widely used. Future studies with more uniform approaches to thresholds, analysis and study conduct may provide a
more homogeneous estimate than the one that has been available from the included studies we have identified.
Footnotes
1 Meta-analytic estimate of sensitivity derived from the HSROC model at a fixed value of specificity. We did not compute
summary estimates of sensitivity and specificity because the studies that contributed to the estimation of the summary ROC
curve used various thresholds.
2 We derived the median proportion converting (reported as a percentage) and range using all the studies included in the
analysis for each target condition.
3 We computed missed and over-diagnosed numbers using the median proportion converting to each target condition.
Additional tables 
1 Classification systems for describing mild cognitive impairment according to Matthews 2008
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System Description Impairment
Age-related cognitive change
ACMI Age-consistent
memory
impairment
Memories aging in accord with normative expectations; individual aged 50 to 79 and reports
a decline in memory verified using objective memory testing performance (within ± 1
standard deviation of aged norms on 75% of tests (memory) administered); preserved
general functioning.
ARCD Age-related cognitivedecline
Objectively identified decline in memory and cognitive functioning considered to be a normal
consequence of aging.
Category systems
SMC Subjective memory
complaint
Self-reported decline in memory.
MMSE
MCI
Mini-Mental State
Examination
Classification based on MMSE cut-offs (maximum score 30). 'Normal' defined as a score
from 27 to 30; MCI defined as a score from 22 to 26; and 'impaired' defined as a score < 21.
Pathological decline
MNCD  
Mild neurocognitive
disorder
Impairment resulting from a general medical condition; reported decline in cognitive
functioning supported by formal testing; deficits observed in at least 2 areas of cognitive
functioning; interference in social, occupational, or other areas of functioning.
CIND Cognitive impairmentno dementia
Cognitive impairment in one or more domains (including memory and non-memory domains)
that can have a variety of aetiologies.
BSF
Benign senescent
Forgetfulness
Impairment in remote memory and intact recent memory; awareness of the impairment and
use of compensatory
strategies.
AAMI Age-associatedmemory impairment
Subjective and objective memory loss associated with normal aging; individual aged 50 and
older and shows adequate intellectual function (i.e. without dementia).
MD Minimal dementia Cognitive impairment in memory and minor and variable errors in orientation; no evidence ofimpaired occupational or social functioning; self care unimpaired.
LCD Limited cognitivedisturbance
Reported decline in memory with use of compensatory strategies; occasional forgetfulness
(e.g. names, places); 1 or 2 errors on cognitive (memory) testing.
QD Questionabledementia
Impaired memory and non-memory test performance; no significant activity of daily living or
instrumental activity of daily living interference.
AACD Age-associatedcognitive decline
Self- or informant report of cognitive decline (gradual and present for 6 months); objective
difficulties in any of the following domains: learning and memory, attention and
concentration, thinking, language, and visuospatial functioning
MCD Mild cognitivedisorder
Decline in cognitive performance, including memory impairment and learning or
concentration difficulties; complaint confirmed by cognitive tests; may precede, accompany,
or follow a wide variety of infections or physical disorders.
Mayo Clinic Criteria
N-MCI Non-amnestic mild
cognitive impairment
Subjective memory complaint; normal general cognitive function; normal range of activities
of daily living; objective impairment in 1 or more domains other than memory.
A-MCI Amnestic mildcognitive impairment
Subjective memory complaint; normal general cognitive function; normal range of activities
of daily living; impaired memory performance; normal non-memory test performance
M-MCI Multiple mild cognitiveimpairment
Subjective memory complaint; normal general cognitive function; normal range of activities
of daily living; impaired memory and nonmemory test performance
Footnotes
2 Criteria for the diagnosis of mild cognitive impairment
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Petersen 1999
Memory complaint, preferably corroborated by an informant.1.
Impaired memory function compared for age and education.2.
Preserved general cognitive function.3.
Intact activities of daily living.4.
Not demented.5.
Petersen 2004
 
4 subtypes of MCI were identified:
Amnesic mild cognitive impairment, single domain – isolated memory impairment of more than 1.0 SD compared with the1.
age- and education-specific norms, and no difficulty in any other area of cognitive functioning.
Amnesic mild cognitive impairment, multiple domain – 2 or more cognitive domains are impaired, 1 of which is memory2.
impairment (impairment of more than 1.0 SD below the mean of the respective age- and education-matched population).
Non-amnesic mild cognitive impairment, single domain – impairment in a single domain other than memory of more than3.
1.0 SD.
Non-amnesic mild cognitive impairment, multiple domains – impairments in 2 or more domains of more than 1.0 SD but4.
no memory impairment.
 
All 4 subtypes of mild cognitive impairment also have to meet the following criteria:
a)  the presence of a complaint about memory – participants or informants (or both) reporting memory impairment.
b)  intact ability to perform activities of daily living – forgetfulness not compromising overall functional ability; impairment
owing to physical disease not sufficient for exclusion.
c)   absence of dementia – assessed by DSM–IV criteria.
 
Morris 1993
 
Clinical Dementia Rating (CDR) is a scale used to classify patients along a continuum from normal aging through
Alzheimer’s disease. This scale describes a continuum from normal (CDR 0) through questionable dementia or MCI (CDR
0.5) to mild (CDR 1), moderate (CDR 2), and severe (CDR 3) dementia.
 
Patient's cognitive and functional performances are assessed in 6 areas: memory, orientation, judgement and problem
solving, community affairs, home and hobbies, and personal care. Scores in each of these areas are combined to obtain the
total score.
Footnotes
MCI: mild cognitive impairment
3 Demographic and participant characteristics of participants included in analysis
Study N / n
(included
in
analysis)
Age
converters
(non-
converters)
Gender
(M %) 
MMSE
score
converters
(non-
converters)
APOE Ɛ4
carrier
(%)
MCI
diagnostic
criteria
Sampling Sources of
referral
Sources of
recruitment
(setting)
Anchisi 2005
(Italy)
 
67/48
 
71.1 ± 73.9
(65.0 ± 9.0)
25 (52.1)  
26.6 ± 1.7
(28.4 ± 1.1)
Not
reported
Patterson
2010
Consecutive
sample
(email from
the author
on 22nd
October
2013)
GP
surgeries
(email from
the author
on 22nd
October
2013)
Outpatients
from
4 University
Departments
(Milan,
Brescia,
Cologne and
Dresden)
(email on
22nd October
2013)
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Study N / n
(included
in
analysis)
Age
converters
(non-
converters)
Gender
(M %) 
MMSE
score
converters
(non-
converters)
APOE Ɛ4
carrier
(%)
MCI
diagnostic
criteria
Sampling Sources of
referral
Sources of
recruitment
(setting)
 
Arnáiz 2001
(Sweden)
20/20  
64.9 ± 8.3
(60.1 ± 8.4)
12 (60.0) 26.7 ± 1.8
(27.2 ± 2.9)
Not
reported
Global
Deterioration
Scale
Consecutive
sample
Not
reported
Geriatric
University
clinic
Berent 1999
(USA)
20/20  
70.2 ± 5.5
Total
sample
13 (65.0)  
26.0 ± 1.9
Total
sample
Not
reported
AAMI
criteria
Not
reported
Not
reported
 
Cognitive
disorders
University
clinic
Chételat 2003
(France)
19/17  
73.0 ± 5.1
(67.8 ± 7.0)
8 (45.2)  
26.3 ± 1.0
(27.8 ± 1.2)
Not
reported
Petersen
2001
Not
reported
Not
reported
Not reported
Clerici 2009
(Italy)
30/26 74.2 ± 6.9
Total
sample
10 (33.3) 26.2 ± 1.7
Total
sample
Not
reported
Petersen
2004 and
CDR = 0.5
criteria
Not
reported
GP
surgeries
or
specialists
(85%) or
self referral
(15%)
 
University
Centre for
Research and
Treatment
Drzezga 2005
(Germany)
30/30  
74.7 ± 4.7
(67.6 ± 2.0)
14 (46.7)  
25.9 ± 2.1
(27.6 ± 1.5)
17 (56.7) Petersen
1999 and
CDR = 0.5
criteria
Not
reported
GP
surgeries
or
specialists
or other
institutions
 
University
Research
Unit
Fellgiebel
2007
(Germany)
16/16  
69.5 ± 7.9
(68.8 ±
10.0)
9 (56.2)  
24.3 ± 1.5
(27.3 ± 1.8)
Not
reported
Petersen
1999
Consecutive
sample
Not
reported
 
University
memory clinic
Galluzzi 2010
(Italy)
90/38 72.0 ± 7.1
Total
sample
 
37 (41.1)
26.1 ± 1.8
Total
sample
 
35 (38.9)
Petersen
1999
Consecutive
sample
Not
reported
Outpatient
memory clinic
Herholz 2011
(USA)
ADNI
participants
94/94 75.0 ± 7.6
Total
sample
66 (70.2) 2671 ± 1.6
Total
sample
Not
reported
Petersen
2010 &
CDR = 0.5
Not
reported
Not
reported
 
Multicentre
(not specified)
Landau 2010
(USA)
ADNI
participants
85/85  
78.3 ± 7.5
(78.0 ± 7.4)
56 (65.9)  
26.4 ± 1.7
(27.3 ± 1.6)
25 (29.4) Petersen
2010 &
CDR=0.5
Not
reported
Not
reported
 
Multicenter
(not specified)
Mosconi 2004
(Italy)
37/37  
69.0 ± 4.0
(63.0 ± 8.0)
17 (45.9)  
23.9 ± 1.7
(28.1 ± 1.6)
16 (43.2) Petersen
2010
Not
reported
Not
reported
Not reported
Nobili 2008
(Italy)
36/33  
77.3 ± 4.8
(74.6 ± 5.4)
13 (39.4)  
69.0 ± 4.0
(63.0 ± 8.0)
Not
reported
on all MCI
included
in
analysis
Petersen
2004
Not
reported
Not
reported
 
Outpatients
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Study N / n
(included
in
analysis)
Age
converters
(non-
converters)
Gender
(M %) 
MMSE
score
converters
(non-
converters)
APOE Ɛ4
carrier
(%)
MCI
diagnostic
criteria
Sampling Sources of
referral
Sources of
recruitment
(setting)
Ossenkoppele
2012a
(Netherlands)
15/12 67.0 ± 7.0
Sample
analysed
9 (75%)
Sample
analysed
75.0 ± 7.6
Sample
analysed
8 (66.7)
Sample
analysed
Petersen
1999
Not
reported
Not
reported
Not reported
Ossenkoppele
2012b
(Netherlands)
30/12 64.0 ± 9.0
Total
sample
23 (30.4)
Total
sample
75.0 ± 7.6
Total
sample
Not
reported
Petersen
2001
Not
reported
Not
reported
 
Outpatient
University
memory clinic
 
Pardo 2010
(USA)
 
19/18
Reader 1
19/19
Reader 2
Mean 80.0
(range 54 -
83)
Total
sample
Not
reported
Not
reported
Not
reported
Petersen
1999
Not
reported
Not
reported
Geriatric,
Research,
Education
and Medical
Centre
Unclear
Schmand
2012
(Netherlands)
ADNI
participants
89/89 Not
reported on
the sample
with ¹⁸F-
FDG scan
(N = 89)
Not
reported
on the
sample
with ¹⁸F-
FDG
scan (N =
89)
Not
reported on
the sample
with ¹⁸F-
FDG scan
(N = 89)
Not
reported
on the
sample
with ¹⁸F-
FDG scan
(N = 89)
Petersen
2010 &
CDR = 0.5
Not
reported
Not
reported
 
Multicentre
(not specified)
Footnotes
ADNI: Alzheimer's Disease neuroimaging initiative
4 Index test and numbers of converters to Alzheimer’s disease dementia
Study Threshold
(prespecified
Yes/No)
Image scaling Discriminating
brain area
Image
analysis
Time
between
FDG
injection
and PET
acquisition
(min)
¹⁸F-FDG
dose
Number of
¹⁸F-FDG
positive
(%)
Number of
converters
(%)
Duration
of follow-
up
Mean
(months)
/
Maximum
(years)
Anchisi 2005
(Italy)
 
rCGMglc of
temporo-parietal
and posterior
cingulate of 1.138
(No)
Regional
sensorimotor
FDG uptake
ratio (p 1730)
Bilateral
parietal and
posterior
cingulate
cortex
SPM99 Not
reported
Not
reported
19 (40)
(calculated
in
RevMan5)
14 (29) Median:
12
months
Range:
12 - 27
months
Arnáiz 2001
(Sweden)
rCGMglc of left
temporo-parietal
region 13 mm
above the basal
ganglia
(Model I)
(No)
Sensorimotor
area of the
cortex 26 mm
above the level
of the basal
ganglia (p 852)
Temporo-
parietal cortex
SPSS
(Herholz
1999)
60 Not
reported
8 (40)
(calculated
in
RevMan5)
9 (45) 36.5
months
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Study Threshold
(prespecified
Yes/No)
Image scaling Discriminating
brain area
Image
analysis
Time
between
FDG
injection
and PET
acquisition
(min)
¹⁸F-FDG
dose
Number of
¹⁸F-FDG
positive
(%)
Number of
converters
(%)
Duration
of follow-
up
Mean
(months)
/
Maximum
(years)
Berent 1999
(USA)
rCGMglc of
diagnostic index
based on Z-
scores of the
parietal cortex
(No)
Thalamus (p
11)
Frontal,
temporal,
parietal and
occipital
regions
normalised to
the thalamus
3D-SSP Not
reported
370 MBq 10 (50) 10 (50) 3 years
Chételat 2003
(France)
 
rCGMglc at Z-
score of > 3.09
Thresholding was
set at 80% of
whole brain mean
of control
subjects
(No)
FDG uptake
normalised by
and adjusted
to the person’s
global uptake
(p 1375)
Right
temporo-
parietal and
posterior
cingulate
SPM99 Not
reported
Not
reported
7 (41)
right
temporo-
parietal
region
8 (47.0)
posterior
cingulate
7 (41) 18
months
Clerici 2009
(Italy)
rCGMglc
lower than the
control group
corresponding to
a P value < 0.01
level)
(Yes)
Global counts
were
normalised by
proportional
scaling to
remove
confounding
effects due to
global changes
(Del Sole
2008)
Posterior
gyrus
cingulate and
bilateral
inferior frontal
cortex
SPM(t) 45 185-370
MBq
23 (88.5) 13 (50) 1.5 years
aMCI
group.
3 years
snaMCI
group
Drzezga 2005
(Germany)
rCGMglc at
Z-score of > 1.64
(1-tail)
corresponding to
a P value of 0.05
(1-tail)
(Yes)
Not
reported
Orbitofrontal,
prefrontal,
premotor,
central,
parietal
superior and
inferior,
occipital,
temporal
anterior,
temporal
posterior and
posterior
cingulate
3D-SSP 30 370 MBq 13 (43) 12 (40) 16 ± 2
months
Fellgiebel
2007
(Germany)
rCGMglc at
significantly
decreased Z-
score > 2 in more
than 50 adjacent
pixels
(Yes)
 
Sensorimotor
area of the
cortex
(transaxial
images parallel
to the
intercomissural
line)
(Fellgiebel
2004)
Parietal
mesial or
posterior
cingulate and
temporal
regions
SPSS
(Fellgiebel
2004)
30
(
Fellgiebel
2004)
180
MBq
(
Fellgiebel
2004)
7 (44) 4 (25) 19.6 ±
9.0
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Study Threshold
(prespecified
Yes/No)
Image scaling Discriminating
brain area
Image
analysis
Time
between
FDG
injection
and PET
acquisition
(min)
¹⁸F-FDG
dose
Number of
¹⁸F-FDG
positive
(%)
Number of
converters
(%)
Duration
of follow-
up
Mean
(months)
/
Maximum
(years)
Galluzzi 2010
(Italy)
rCGMglc of
t sum > 11.090
(email from the
author)
(Herholz 2002)
(Yes)
Cerebellum Temporo-
parietal,
hippocampus
and posterior
cingulate
SPSS Not
reported
Not
reported
28 (74) 14 (37) 20.6.6 ±
9.7
Herholz 2011
(USA)
ADNI
participants
rCGMglc of
t sum > 11.090
(Herholz 2002)
(Yes)
Global cortex Temporal and
parietal lobes
 
PALZ (PMOD
software)
30 - 60 Not
reported
38 (40) 30 (32) 2 years
Landau 2010
(USA)
ADNI
participants
rCGMglc of 1.21
(No)
Cerebellar
vermis and
pons
ROI interest
were study-
independent,
frequently
associated
with decline in
AD and MCI.
No further
details.
SPM5 30 - 60 Not
reported
51 (60) 28 (33)  
1.9 ± 0.4
years
Range: 2
- 3 years
Mosconi 2004
(Italy)
rCMRglc
significantly
reduced in certain
cerebral areas
with emphasis on
the inferior
parietal lobule
(IPL).
(No)
Global cortex Precuneus,
anterior and
posterior
cingulate,
inferior
parietal lobe,
superior,
middle and
inferior frontal
gyrus, on
both
hemispheres
SPM99 19 ± 3 110 - 370
MBq
4 (10.5) 8 (22) 12 ± 0.6
Nobili 2008
(Italy)
Visual inspection
rCGMglc
threshold not
reported
(No)
Global cortex 25 VROI in
each
hemisphere
Computerized
Brain Atlas
(CBA;
Applied
Medical
Imaging©,
Uppsala,
Sweden)
45 370 MBq 11 (33) 11 (33) 21.1 ±
10.9
months
Ossenkoppele
2012a
(Netherlands)
 
Visual inspection
and SUVr of ROIs
(threshold not
reported) (No)
Cerebellar
grey matter
Frontal,
parietal and
latero-
temporal and
medial
temporal
lobes and
posterior
cingulate
PMOD
Alzheimer
discrimination
tool (PALZ)
45 - 60 150 ± 17
MBq
4 (33) 4 (33) 30
Range: 2
- 4 years
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Study Threshold
(prespecified
Yes/No)
Image scaling Discriminating
brain area
Image
analysis
Time
between
FDG
injection
and PET
acquisition
(min)
¹⁸F-FDG
dose
Number of
¹⁸F-FDG
positive
(%)
Number of
converters
(%)
Duration
of follow-
up
Mean
(months)
/
Maximum
(years)
Ossenkoppele
2012b
(Netherlands)
 
Visual inspection
and SUVr of ROIs
(threshold not
reported) (No)
Cerebellar
grey matter (p
3)
Frontal,
parietal,
occipital, and
latero-
temporal and
medial
temporal
lobes and
posterior
cingulate
PMOD
Alzheimer
discrimination
tool (PALZ)
45-60 185 MBq 5 (42) 6 (50) 2 years
 
Pardo 2010
(USA)
 
Visual inspection
Hypomethabolism
if < 50% of the
cubes had the
label MCI or
normal
(Only SVM
analysis used
thresholds)
(No)
 
PET scans
were adjusted
to a whole-
brain mean
activity and
stereotactically
normalised by
using
Neurostat (p
328)
Frontal,
parietal,
occipital, and
latero-
temporal and
medial
temporal
lobes and
posterior
cingulate
SVM Not
reported
5 mCi/70
kg
 
Reader 1:
6(32)
Reader 2:
10 (53)
 
8 (44)
9 (47)
3 years
Schmand
2012
(Netherlands)
ADNI
participants
rCGM value of <
1.20
(Email from the
author)
(Yes)
Not
reported
Right and left
angular
gyrus,
bilateral
posterior
cingulate
gyrus and left
middle/inferior
temporal
gyrus
SPSS Not
reported
Not
reported
18 (20) 38 (43) 2.7 ± 0.9
Range:
0.5 - 4.6
years
Footnotes
ADNI: Alzheimer's Disease neuroimaging initiative
RevMan5: Review Manager 5 software
SUVr: standardised uptake value ratio
VROI: volumetric region of interest
5 Summary of test accuracy at study level for conversion to Alzheimer’s disease dementia
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Studies included in meta-analysis
Study ID Participants (n) Sensitivity (%)Specificity (%)% of MCI with ¹⁸F-FDG PET positivity 
Anchisi 2005 48 93 82 40
Arnáiz 2001 20 67 82 40
Berent 1999 20 70 70 50
Chételat 2003
(temporo-parietal brain region)
17 100 100 41
Clerici 2009 26 92 15 88
Drzezga 2005 30 92 89 43
Fellgiebel 2007 16 100 75 44
Galluzzi 2010 38 79 29 74
Herholz 2011 (ADNI study) 94 57 67 40
Mosconi 2004 37 38 97 10.5
Nobili 2008 33 82 91 33
Ossenkoppele 2012a 12 75 88 33
Ossenkoppele 2012b 12 83 100 42
Pardo 2010(Reader 1) 18 25 60 32
Studies included only in descriptive analysis
Chételat 2003
(posterior cingulate brain region)
17 100 90 47
Landau 2010 (ADNI study) 85 75 47 60
Pardo 2010 (Reader 2) 17 33 30 53
Schmand 2012 (ADNI study) 98 24 82 20
Footnotes
ADNI: Alzheimer's Disease neuroimaging initiative
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Classification pending references
Data and analyses 
Data tables by test
Test StudiesParticipants
1 18FFDG-PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo-parietal
region and Herholz 2011 ADNI study) 14 421
2 18FFDG-PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo-parietal
region and Landau 2010 ADNI study) 14 412
3 18FFDG-PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo-parietal
region and Schmand 2012 ADNI study) 14 416
4 18FFDG-PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 posterior
cingulate region and Herholz 2011 ADNI study) 14 421
5 18FFDG-PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 temporo-parietal
region and Herholz 2011 ADNI study) 14 422
6 18FFDG-PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 posterior
cingulate region and Herholz 2011 ADNI study) 14 422
7 18FFDG-PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010) 5 106
8 18FFDG-PET Conversion from MCI to All dementia (with Reader 2 Pardo 2010) 5 107
Figures
Figure 1
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Caption
Study flow diagram.
Figure 2
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Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 3
Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 4 (Analysis 1) 
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Caption
Forest plot of ¹⁸F-FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo-parietal region
and Herholz 2011 ADNI study).
Figure 5 (Analysis 1) 
Caption
Summary ROC plot of ¹⁸F-FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo-parietal
region and Herholz 2011 ADNI study).
Figure 6 (Analysis 7) 
Caption
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Forest plot of ¹⁸F-FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010).
Figure 7 (Analysis 7) 
Caption
Summary ROC plot of ¹⁸F-FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010).
Sources of support 
Internal sources
No sources of support provided
External sources
No sources of support provided
Feedback 
Appendices 
1 Sources searched and search strategies used
 
Source
Search strategy Hits
retrieved
1. MEDLINE In-process
and other non-indexed
citations and MEDLINE
1950-present (January
2013) (Ovid SP)
 
1. exp Dementia/
2. Cognition Disorders/
3. (alzheimer$ or dement$).ti,ab.
4. ((cognit$ or memory or cerebr$ or mental$) adj3 (declin$ or impair$ or los$ or
deteriorat$ or degenerat$ or complain$ or disturb$ or disorder$)).ti,ab.
5. (forgetful$ or confused or confusion).ti,ab.
6. MCI.ti,ab.
7. ACMI.ti,ab.
8. ARCD.ti,ab.
 
July
2012:
1480
January
2013: 120
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9. SMC.ti,ab.
10. CIND.ti,ab.
11. BSF.ti,ab.
12. AAMI.ti,ab.
13. MD.ti,ab.
14. LCD.ti,ab.
15. QD.ti,ab.
16. AACD.ti,ab.
17. MNCD.ti,ab.
18. MCD.ti,ab.
19. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
20. or/1-19
21. "Positron emission tomography".ti,ab.
22. *Positron-Emission Tomography/
23. PET.ti,ab.
24. "FDG-PET".ti,ab.
25. ("PET-FDG" or "18f-fdg" or "fdg uptake").ti,ab.
26. fluodeoxyglucose*.ti,ab.
27. fluorodexyglucose*.ti,ab.
28. Fluorodeoxyglucose F18/
29. or/21-28
30. glucose metabolism.ti,ab.
31. hypometabolism.ti,ab.
32. cerebral metabolic rate.ti,ab.
33. metabolic activity.ti,ab.
34. hypoperfusion.ti,ab.
35. (CMRgl or rCMRGlu).ti,ab.
36. or/30-35
37. 20 and 29 and 36
38. disease progression/
39. (dement* or alzheimer* or AD or MCI).ti,ab.
40. exp *Dementia/
41. 39 or 40
42. 41 and 38
43. 29 and 42
44. 37 or 43
45. exp Dementia/di
46. 36 and 45
47. 44 or 46
2. EMBASE
1980-2013 January week
2 (Ovid SP)
 
1. exp dementia/
2. (alzheimer* or dement*).ti,ab.
3. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
4. (forgetful* or confused or confusion).ti,ab.
5. MCI.ti,ab.
6. ACMI.ti,ab.
 
July
2012:
3181
January
2013: 567
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7. ARCD.ti,ab.
8. SMC.ti,ab.
9. CIND.ti,ab.
10. BSF.ti,ab.
11. AAMI.ti,ab.
12. LCD.ti,ab.
13. QD.ti,ab.
14. AACD.ti,ab.
15. MNCD.ti,ab.
16. MCD.ti,ab.
17. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
18. ("nMCI" or "aMCI" or "mMCI").ti,ab.
19. or/1-18
20. "positron emission tomography".ti,ab.
21. *positron emission tomography/
22. PET.ti,ab.
23. "FDG-PET".ti,ab.
24. ("PET-FDG" or "18f-fdg" or "fdg uptake").ti,ab.
25. fluodeoxyglucose*.ti,ab.
26. fluorodexyglucose*.ti,ab.
27. fluorodeoxyglucose f 18/
28. or/20-27
29. glucose metabolism.ti,ab.
30. hypometabolism.ti,ab.
31. "cerebral metabolic rate*".ti,ab.
32. metabolic activity.ti,ab.
33. hypoperfusion.ti,ab.
34. (CMRgl or rCMRGlu).ti,ab.
35. or/29-34
36. 19 and 28 and 35
37. disease course/
38. (dement* or alzheimer* or AD or "cognit* impair*" or MCI).ti,ab.
39. exp dementia/
40. 38 or 39
41. (diagnosis or sensitivity or specificity or "disease progression" or converted or
conversion).ti,ab.
42. 37 or 41
43. 40 and 42
44. 28 and 43
45. 36 or 44
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Source
Search strategy Hits
retrieved
3. PSYCINFO
1806-January week 2
2013 (Ovid SP)
 
1. exp Dementia/
2. (alzheimer* or dement*).ti,ab.
3. ((cognit* or memory or cerebr* or mental*) adj3 (declin* or impair* or los* or
deteriorat* or degenerat* or complain* or disturb* or disorder*)).ti,ab.
4. (forgetful* or confused or confusion).ti,ab.
5. MCI.ti,ab.
6. ACMI.ti,ab.
7. ARCD.ti,ab.
8. SMC.ti,ab.
9. CIND.ti,ab.
10. BSF.ti,ab.
11. AAMI.ti,ab.
12. LCD.ti,ab.
13. QD.ti,ab.
14. AACD.ti,ab.
15. MNCD.ti,ab.
16. MCD.ti,ab.
17. ("N-MCI" or "A-MCI" or "M-MCI").ti,ab.
18. ("nMCI" or "aMCI" or "mMCI").ti,ab.
19. or/1-18
20. exp Positron Emission Tomography/
21. "positron emission tomography".ti,ab.
22. PET.ti,ab.
23. "FDG-PET".ti,ab.
24. ("PET-FDG" or "18f-fdg" or "fdg uptake").ti,ab.
25. fluodeoxyglucose*.ti,ab.
26. fluorodexyglucose*.ti,ab.
27. or/20-26
28. "glucose metabolism".ti,ab.
29. hypometabolism.ti,ab.
30. "cerebral metabolic rate*".ti,ab.
31. metabolic activity.ti,ab.
32. hypoperfusion.ti,ab.
33. (CMRgl or rCMRGlu).ti,ab.
34. or/28-33
35. 19 and 27
36. 34 and 35
 
July
2012: 479
January
2013: 59
4. Biosis previews 1926
to present (January
2013) (ISI Web of
Knowledge)
 
Topic=(dementia OR cognition OR MCI OR alzheimer* OR AD OR lewy OR memory
OR cognitive OR FTLD) AND Topic=("Positron emission tomography" OR PET OR
"FDG-PET" OR "PET-FDG" OR "18f-fdg" OR "fdg uptake" OR fluodeoxyglucose* OR
fluorodexyglucose*) AND Topic=("glucose metabolism" OR hypometabolism OR
"cerebral metabolic rate" OR "metabolic activity" OR hypoperfusion OR CMRgl OR
rCMRGlu)
Timespan=All Years. Databases=BIOSIS Previews.
Lemmatization=On
 
July
2012:
1176
January
2013: 83
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Source
Search strategy Hits
retrieved
5. Web of Science and
conference proceedings
(1945-present - January
2013)
 
Topic=(dementia OR cognition OR MCI OR alzheimer* OR AD OR lewy OR memory
OR cognitive OR FTLD) AND Topic=("Positron emission tomography" OR PET OR
"FDG-PET" OR "PET-FDG" OR "18f-fdg" OR "fdg uptake" OR fluodeoxyglucose* OR
fluorodexyglucose*) AND Topic=("glucose metabolism" OR hypometabolism OR
"cerebral metabolic rate" OR "metabolic activity" OR hypoperfusion OR CMRgl OR
rCMRGlu)
Timespan=All Years. Databases=BIOSIS Previews.
Lemmatization=On
 
July
2012:
2082
January
2013: 150
6. LILACS (January
2013) (BIREME)
positron OR PET OR tomografía OR hypometabolism OR hypoperfusion OR CMRgl
OR rCMRGlu [Words] and demências OR dementia OR dementias OR demência OR
Alzheimer OR Alzheimers OR Alzheimer's OR cognitive OR cognitive OR cognitive OR
cognition OR "déficit cognitive" OR cognición OR cognição OR Memória OR memory
OR Memoria OR "frontotemporal lobar degeneration" OR "degeneração lobar
frontotemporal" OR FTLD OR FTD OR "pick's disease" OR "primary progressive
aphasia" [Words]
 
July
2012: 296
January
2013: 3
TOTAL before de-duplication  
July
2012:
8694
January
2013: 982
TOTAL after de-dupe and first-assess  
July
2012: 149
January
2013: 248
1 exp Dementia/
2 Cognition Disorders/
3 Mild Cognitive Impairment/
4 (alzheimer$ or dement$).ti,ab.
5 ((cognit$ or memory or cerebr$ or mental$) adj3 (declin$ or impair$ or los$ or deteriorat$ or degenerat$ or complain$ or
disturb$ or disorder$)).ti,ab.
6 (forgetful$ or confused or confusion).ti,ab.
7 MCI.ti,ab.
8 ACMI.ti,ab.
9 ARCD.ti,ab.
10 SMC.ti,ab.
11 CIND.ti,ab.
12 BSF.ti,ab.
13 AAMI.ti,ab.
14 LCD.ti,ab.
15 AACD.ti,ab.
16 MNCD.ti,ab.
17 MCD.ti,ab.
18 or/1-17
19 "Positron emission tomography".ti,ab.
20 exp Tomography, Emission-Computed/
21 PET.ti,ab.
22 tomograph*.ti,ab.
23 or/19-22
24 FDG.ti,ab.
25 ("18f-fdg" or 18fdg or fdg18).ti,ab.
26 Fluorodeoxyglucose.ti,ab.
27 Fluorodeoxyglucose F18/
28 Glucose/
29 glucose metabol*.ti,ab.
30 cerebral metabolic rate.ti,ab.
31 (CMRgl or rCMRGlu).ti,ab.
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32 or/24-31
33 18 and 23 and 32
34 exp Dementia/di
35 34 AND 32
36 33 OR 35
2 Two-by-two tables
Table 1: Conversion from MCI to Alzheimer’s disease dementia
Index test
information
References standard information
ADD present ADD absent
Index test positive ¹⁸F-FDG PET+ who convert to
ADD (TP)
¹⁸F-FDG PET+ who remain MCI (FP) & ¹⁸F-FDG PET+ who convert
to non-AD(FP)
Index test negative ¹⁸F-FDG PET- who convert to
ADD (FN)
¹⁸F-FDG PET- who remain MCI (TN) & ¹⁸F-FDG PET-who convert to
non-AD (TN)
Table 2: Conversion from MCI to non-Alzheimer’s disease dementia
Index test
information
References standard information
Non-ADD present Non-ADD absent
Index test positive ¹⁸F-FDG PET+ who convert to non-
ADD (TP)
¹⁸F-FDG PET+ who remain MCI (FP) & ¹⁸F-FDG PET+ who
convert to ADD (FP)
Index test negative ¹⁸F-FDG PET- who convert to non-
ADD (FN)
¹⁸F-FDG PET- who remain MCI (TN) & ¹⁸F-FDG-PET- who
convert to ADD (TN)
Table 3: Conversion from MCI to any forms of dementia
Index test informationReferences standard information
Dementia present (any form of dementia) Dementia absent
Index test positive ¹⁸F-FDG PET+ who convert to any forms of dementia (TP) ¹⁸F-FDG PET+ who remain MCI (FP)
Index test negative ¹⁸F-FDG PET- who convert to any forms of dementia (FN) ¹⁸F FDG-PET- who remain MCI (TN)
3 Appendix: Assessment of methodological quality table QUADAS-2 tool
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DOMAIN PATIENT SELECTION   INDEX TEST  REFERENCE
STANDARD
FLOW AND TIMING 
Description Describe methods of
participant
selection: Describe
included patients (prior
testing, presentation,
intended use of index test
and setting): 
Describe the index
test and how it was
conducted and
interpreted
Describe the
reference standard
and how it was
conducted and
interpreted
Describe any participants who did
not receive the index test(s) and/or
reference standard or who were
excluded from the 2 x 2 table (refer
to flow diagram): Describe the time
interval and any interventions
between index test(s) and
reference standard
Signalling
questions
(yes/no/unclear)
Was a consecutive or
random sample of patients
enrolled?
Were the index test
results interpreted
without knowledge
of the results of the
reference
standard?
Is the reference
standard likely to
correctly classify the
target condition?
Was there an appropriate interval
between index test(s) and
reference standard?
Was a case-control design
avoided?
If a threshold was
used, was it
prespecified?
Were the reference
standard results
interpreted without
knowledge of the
results of the index
test?
Did all participants receive a
reference standard?
Did the study avoid
inappropriate exclusions?
Did all participants receive the
same reference standard?
Were all participants included in the
analysis?
Risk of bias:
High/low/ unclear
Could the selection of
participants have
introduced bias?
Could the conduct
or interpretation of
the index test have
introduced
bias?      
Could the reference
standard, its
conduct, or its
interpretation have
introduced bias?
Could the participant flow have
introduced bias? 
Concerns
regarding
applicability:
High/low/ unclear
Are there concerns that the
included participants do
not match the review
question?
Are there concerns
that the index test,
its conduct, or
interpretation differ
from the review
question?
Are there concerns
that the target
condition as defined
by the reference
standard does not
match the review
question?
 
4 Appendix: Anchoring statements for quality assessment of ¹⁸F-FDG-PET biomarker diagnostic studies
Table 1: Review question and inclusion criteria
Category Review Question Inclusion Criteria
Patients Participants with mild cognitive
impairment, no dementia
Participants fulfilling the criteria for the clinical diagnosis of
MCI at baseline
Index Test ¹⁸F-FDG PET biomarker ¹⁸F-FDG PET biomarker
Target
Condition
Alzheimer’s disease dementia
(conversion from MCI to Alzheimer’s
disease dementia)
 
Any other forms of dementia (conversion
from MCI to any other forms of dementia)
Alzheimer’s disease dementia (conversion from MCI to
Alzheimer’s disease dementia)
 
Any other forms of dementia (conversion from MCI to any other
forms of dementia)
Reference
Standard
NINCDS-ADRDA; DSM; ICD; McKeith
criteria; Lund criteria; NINDS-ARIEN
criteria
NINCDS-ADRDA; DSM; ICD; McKeith criteria; Lund criteria;
NINDS-ARIEN criteria
Outcome N/A Data to construct 2 x 2 table
Study Design N/A Longitudinal cohort studies and nested case-control studies if they
incorporate a delayed verification design (case-control nested in
cohort studies)
Anchoring statements for quality assessment of ¹⁸F-FDG PET biomarker studies
We provide some core anchoring statements for quality assessment of diagnostic test accuracy reviews of ¹⁸F-FDG
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PET biomarker in dementia. These statements are designed for use with the QUADAS-2 tool and are based on the
guidance for quality assessment of diagnostic test accuracy reviews of IQCODE in dementia (Quinn 2014). 
During the two-day, multidisciplinary focus group and the piloting/validation of the  guidance, it was clear that certain issues
were key to assessing quality, while other issues were important to record but less important for assessing overall quality. To
assist, we describe a 'weighting' system. Where an item is weighted 'high risk' then that section of the QUADAS-2 results
table is likely to be scored as at high risk of bias. For example in dementia diagnostic test accuracy studies, ensuring that
clinicians performing dementia assessment are blinded to results of index test is fundamental. If this blinding was not present
then the item on reference standard should be scored 'high risk of bias', regardless of the other contributory elements.
In assessing individual items, the score of 'Unclear' should only be given if there is genuine uncertainty. In these situations
review authors will contact the relevant study teams for additional information.
Table 2: Anchoring statements to assist with assessment for risk of bias
Question Response
and
weighting
Explanation
Patient Selection
 
Was the sampling method
appropriate?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Where sampling is used, the designs least likely to cause bias are
consecutive sampling or random sampling. Sampling that is based on
volunteers or selecting participants from a clinic or research resource is
prone to bias.
Was a case-control or similar
design avoided?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Designs similar to case-control that may introduce bias are those designs
where the study team deliberately increase or decrease the proportion of
participants with the target condition, which may not be representative.
Some case-control methods may already be excluded if they mix participants
from various settings.
Are exclusion criteria described
and appropriate?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Study will be automatically graded unclear if exclusions are not detailed
(pending contact with study authors). Where exclusions are detailed, the
study will be graded as 'low risk' if exclusions are felt to be appropriate by
the review authors. Certain exclusions common to many studies of dementia
are: medical instability; terminal disease; alcohol/substance misuse;
concomitant psychiatric diagnosis; other neurodegenerative condition.
Exclusions are not felt to be appropriate if ‘difficult to diagnose’ patients are
excluded. Post hoc and inappropriate exclusions will be labelled 'high risk' of
bias.
Index Test
Was ¹⁸F-FDG PET biomarker
assessment/interpretation
performed without knowledge of
clinical dementia diagnosis?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Terms such as “blinded” or “independently and without knowledge of” are
sufficient and full details of the blinding procedure are not required.
Interpretation of the results of the index test may be influenced by knowledge
of the results of reference standard. If the index test is always interpreted
prior to the reference standard then the person interpreting the index test
cannot be aware of the results of the reference standard and so this item
could be rated as ‘yes’.
For certain index tests the result is objective and knowledge of reference
standard should not influence the result, for example level of protein in
cerebrospinal fluid; in this instance the quality assessment may be 'low risk'
even if blinding was not achieved.
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Question Response
and
weighting
Explanation
Were ¹⁸F-FDG PET biomarker
thresholds prespecified?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
For scales and biomarkers there is often a reference point (in units or
categories) above which participants are classified as 'test positive'; this may
be referred to as threshold; clinical cut-off or dichotomisation point. A study
is classified at high risk of bias if the authors define the optimal cut-off post
hoc based on their own study data, because selecting the threshold to
maximise sensitivity and specificity may lead to overoptimistic measures of
test performance.
Certain papers may use an alternative methodology for analysis that does
not use thresholds and these papers should be classified as not applicable.
Reference Standard
 
Is the assessment used for clinical
diagnosis of dementia
acceptable?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Commonly-used international criteria to assist with clinical diagnosis of
dementia include those detailed in DSM-IV and ICD-10. Criteria specific to
dementia subtypes include, but are not limited to, NINCDS-ADRDA criteria
for Alzheimer’s dementia; McKeith criteria for Lewy Body dementia; Lund
criteria for frontotemporal dementia; and the NINDS-AIREN criteria for
vascular dementia. Where the criteria used for assessment are not familiar
to the review authors or the Cochrane Dementia and Cognitive Improvement
group (‘unclear’) this item should be classified as 'high risk of bias'.
 
Was clinical assessment for
dementia performed without
knowledge of the ¹⁸F-FDG PET
biomarker?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Terms such as “blinded” or “independently and without knowledge of” are
sufficient and full details of the blinding procedure are not required.
Interpretation of the results of the reference standard may be influenced by
knowledge of the results of index test.
Participant flow
Was there an appropriate interval
between ¹⁸F-FDG PET biomarker
and clinical dementia
assessment?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
As we test the accuracy of the ¹⁸F-FDG PET biomarker for MCI conversion
to dementia, there will always be a delay between the index test and the
reference standard assessments. The time between reference standard and
index test will influence the accuracy ( Geslani 2005 ; Okello 2009 ; Visser
2006 ), and therefore we will note time as a separate variable (both within
and between studies) and will test its influence on the diagnostic accuracy.
We have set a minimum mean time to follow-up assessment of 1 year. If
more than 16% of participants have assessment for MCI conversion before 9
months this item will score ‘no’.
Did all participants get the same
assessment for dementia
regardless of ¹⁸F-FDG PET
biomarker?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
There may be scenarios where participants who score “test positive” on
index test have a more detailed assessment. Where dementia assessment
differs between participants this should be classified as high risk of bias.
 
Were all participants who received
¹⁸F-FDG PET biomarker
assessment included in the final
analysis?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
If the number of participants enrolled differs from the number of paricipants
included in the 2 x 2 table then there is the potential for bias. If participants
lost to drop-out differ systematically from those who remain, then estimates
of test performance may differ.
If there are drop-outs they should be accounted for; a maximum proportion
of drop-outs to remain at low risk of bias has been specified as 20%.
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Question Response
and
weighting
Explanation
 
Were missing ¹⁸F-FDG PET
biomarker results or
uninterpretable ¹⁸F-FDG PET
biomarker results reported?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Where missing or uninterpretable results are reported, and if there is
substantial attrition (we have set an arbitrary value of 50% missing data), this
should be scored as ‘no’. If those results are not reported, this should be
scored as ‘unclear’ and authors will be contacted.
Anchoring statements to assist with assessment for applicability
Question Explanation 
 
Were included participants
representative of the general
population of interest?
The included participants should match the intended population as described in the
review question. The review authors should consider population in terms of symptoms;
pre-testing; potential disease prevalence; setting 
If there is a clear ground for suspecting an unrepresentative spectrum the item should be
rated poor applicability.
Index test
Were sufficient data on ¹⁸F-FDG
PET biomarker application given
for the test to be repeated in an
independent study?
 
Variation in technology, test execution, and test interpretation may affect estimate of
accuracy. In addition, the background, and training/expertise of the assessor should be
reported and taken into consideration. If ¹⁸F-FDG PET biomarker was not performed
consistently this item should be rated poor applicability.
Reference Standard
 
Was clinical diagnosis of dementia
made in a manner similar to
current clinical practice?
For many reviews, inclusion criteria and assessment for risk of bias will already have
assessed the dementia diagnosis. For certain reviews an applicability statement relating
to reference standard may not be applicable. There is the possibility that a form of
dementia assessment, although valid, may diagnose a far larger proportion of
participants with disease than usual clinical practice. In this instance the item should be
rated poor applicability.
Graphs
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